Nilceya

Overview

nilotinib

kinase inhibitor

• CYP3A4 substrate
• CYP3A4 inhibitor, moderate
• antiplatelet/anticoagulant effects
• gastric pH sensitive
• GI mucosal injury/bleeding risk
• hyperkalemia
• hyperuricemic effects
• hypocalcemia
• hypokalemia
• hyponatremia
• hypophosphatemia
• immunomodulatory effects
• myelosuppressive oncologic agent
• prolongs QT interval (known)

Contraindicated

• cisapride
Nilceya (nilotinib)

+

cisapride

1 interaction

Contraindicated

nilotinib + cisapride

contraindicated: combo may incr. cisapride levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• colchicine
Nilceya (nilotinib)

+

colchicine

1 interaction

Contraindicated

nilotinib + colchicine

CV RISK: avoid combo if renal or hepatic impairment; otherwise, monitor CBC, CK, myopathy s/sx; GOUT or FMF: contraindicated if renal or hepatic impairment; otherwise, use alternative or monitor CBC; decr. colchicine dose during and x14 days after nilotinib use: GOUT PROPHYLAXIS: give colchicine 0.3-0.6 mg/day divided qd-bid; ACUTE GOUT: avoid combo if receiving colchicine for prophylaxis; otherwise, give colchicine 1.2 mg x1 only; FMF: decr. max colchicine dose to 1.2 mg/day divided qd-bid: combo may incr. colchicine levels, risk of myelosuppression, myopathy, rhabdomyolysis, other life-threatening toxicity (hepatic metabolism inhibited, additive effects)

• domperidone
Nilceya (nilotinib)

+

domperidone

1 interaction

Contraindicated

nilotinib + domperidone

contraindicated: combo may incr. domperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• dronedarone
Nilceya (nilotinib)

+

dronedarone

1 interaction

Contraindicated

nilotinib + dronedarone

contraindicated: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

• eliglustat
Nilceya (nilotinib)

+

eliglustat

1 interaction

Contraindicated

nilotinib + eliglustat

CYP2D6 EM: contraindicated if also combined w/ moderate or strong CYP2D6 inhibitor; otherwise, monitor ECG, electrolytes; decr. eliglustat dose to 84 mg qd; CYP2D6 IM: contraindicated if also combined w/ moderate or strong CYP2D6 inhibitor; otherwise, avoid combo; CYP2D6 PM: avoid combo: combo may incr. eliglustat levels, risk of PR or QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• flibanserin
Nilceya (nilotinib)

+

flibanserin

1 interaction

Contraindicated

nilotinib + flibanserin

contraindicated w/in 14 days prior to, during, and x2 days after flibanserin tx: combo may incr. flibanserin levels, risk of CNS depression, psychomotor impairment, severe hypotension (including syncope), other adverse effects (hepatic metabolism inhibited)

• levoketoconazole
Nilceya (nilotinib)

+

levoketoconazole

1 interaction

Contraindicated

nilotinib + levoketoconazole

contraindicated: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

• lomitapide
Nilceya (nilotinib)

+

lomitapide

1 interaction

Contraindicated

nilotinib + lomitapide

contraindicated: combo may incr. lomitapide levels, risk of hepatotoxicity, other adverse effects (hepatic metabolism inhibited)

• pimozide
Nilceya (nilotinib)

+

pimozide

1 interaction

Contraindicated

nilotinib + pimozide

contraindicated: combo may incr. pimozide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• posaconazole
Nilceya (nilotinib)

+

posaconazole

1 interaction

Contraindicated

nilotinib + posaconazole

contraindicated: combo may incr. nilotinib levels, risk of QT prolongation, cardiac arrhythmias, hypokalemia, other adverse effects (hepatic metabolism inhibited; additive effects)

• thioridazine
Nilceya (nilotinib)

+

thioridazine

1 interaction

Contraindicated

nilotinib + thioridazine

contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ziprasidone
Nilceya (nilotinib)

+

ziprasidone

1 interaction

Contraindicated

nilotinib + ziprasidone

contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

Avoid/Use Alternative

• adagrasib
Nilceya (nilotinib)

+

adagrasib

1 interaction

Avoid/Use Alternative

nilotinib + adagrasib

avoid combo: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

• adenovirus vaccine, live
Nilceya (nilotinib)

+

adenovirus vaccine, live

1 interaction

Avoid/Use Alternative

nilotinib + adenovirus vaccine, live

avoid combo; vaccinate at least 4wk before or 3-6mo after nilotinib tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

• alfentanil
Nilceya (nilotinib)

+

alfentanil

1 interaction

Avoid/Use Alternative

nilotinib + alfentanil

use alternative or monitor respiratory rate; consider decr. alfentanil dose: combo may incr. alfentanil levels, risk of CNS and respiratory depression, psychomotor impairment, delayed recovery from anesthesia, other adverse effects (hepatic metabolism inhibited)

• alprazolam
Nilceya (nilotinib)

+

alprazolam

1 interaction

Avoid/Use Alternative

nilotinib + alprazolam

use alternative or monitor respiratory rate; consider decr. alprazolam dose: combo may incr. alprazolam levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• amiloride
Nilceya (nilotinib)

+

amiloride

1 interaction

Avoid/Use Alternative

nilotinib + amiloride

if hypokalemia use, monitor potassium, sodium; otherwise, avoid combo: combo may incr. risk of hyperkalemia, hyponatremia (additive effects)

• amiodarone
Nilceya (nilotinib)

+

amiodarone

1 interaction

Avoid/Use Alternative

nilotinib + amiodarone

avoid combo: combo may incr. amiodarone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• anagrelide
Nilceya (nilotinib)

+

anagrelide

1 interaction

Avoid/Use Alternative

nilotinib + anagrelide

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias, GI or other bleeding, including life-threatening (additive effects)

• apalutamide
Nilceya (nilotinib)

+

apalutamide

1 interaction

Avoid/Use Alternative

nilotinib + apalutamide

avoid combo: combo may decr. nilotinib levels, efficacy; may incr. risk of QT prolongation, cardiac arrhythmias (hepatic metabolism induced; additive effects)

• apomorphine
Nilceya (nilotinib)

+

apomorphine

1 interaction

Avoid/Use Alternative

nilotinib + apomorphine

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• aprepitant
Nilceya (nilotinib)

+

aprepitant

1 interaction

Avoid/Use Alternative

nilotinib + aprepitant

avoid combo w/ oral aprepitant; IV aprepitant use OK: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited)

• arsenic trioxide
Nilceya (nilotinib)

+

arsenic trioxide

1 interaction

Avoid/Use Alternative

nilotinib + arsenic trioxide

avoid combo: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

• artemether/lumefantrine
Nilceya (nilotinib)

+

artemether/ lumefantrine

1 interaction

Avoid/Use Alternative

nilotinib + artemether/ lumefantrine

avoid combo: combo may incr. artemether/lumefantrine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects; may decr. nilotinib levels, efficacy (hepatic metabolism inhibited, additive effects; hepatic metabolism induced)

• asenapine
Nilceya (nilotinib)

+

asenapine

1 interaction

Avoid/Use Alternative

nilotinib + asenapine

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• atazanavir
Nilceya (nilotinib)

+

atazanavir

1 interaction

Avoid/Use Alternative

nilotinib + atazanavir

use alternative or monitor ECG, CBC; decr. nilotinib dose as follows: newly diagnosed CML: if on nilotinib 300 mg bid, decr. to 200 mg qd; if on nilotinib 142 mg bid, decr. to 95 mg qd; resistant or intolerant CML: if on nilotinib 400 mg bid, decr. to 300 mg qd; if on nilotinib 190 mg bid, decr. to 142 mg qd: combo may incr. nilotinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited)

• avapritinib
Nilceya (nilotinib)

+

avapritinib

1 interaction

Avoid/Use Alternative

nilotinib + avapritinib

GIST: use alternative or monitor bleeding s/sx; decr. avapritinib start dose to 100 mg qd; ADVANCED SYSTEMIC MASTOCYTOSIS: use alternative or monitor bleeding s/sx; decr. avapritinib start dose to 50 mg qd; INDOLENT SYSTEMIC MASTOCYTOSIS: avoid combo: combo may incr. avapritinib levels, risk of GI or other bleeding (including life-threatening), other adverse effects (hepatic metabolism inhibited, additive effects)

• azithromycin
Nilceya (nilotinib)

+

azithromycin

1 interaction

Avoid/Use Alternative

nilotinib + azithromycin

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• bedaquiline
Nilceya (nilotinib)

+

bedaquiline

1 interaction

Avoid/Use Alternative

nilotinib + bedaquiline

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• bosentan
Nilceya (nilotinib)

+

bosentan

1 interaction

Avoid/Use Alternative

nilotinib + bosentan

consider alternative: combo may incr. bosentan levels, risk of adverse effects; may decr. nilotinib levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• bosutinib
Nilceya (nilotinib)

+

bosutinib

1 interaction

Avoid/Use Alternative

nilotinib + bosutinib

avoid combo: combo may incr. bosutinib levels, risk of myelosuppression, other adverse effects (hepatic metabolism inhibited)

• brigatinib
Nilceya (nilotinib)

+

brigatinib

1 interaction

Avoid/Use Alternative

nilotinib + brigatinib

use alternative or monitor BP, HR; decr. brigatinib dose by approx. 40% as follows: if taking 180 mg, decr. to 120 mg, if taking 120 mg, decr. to 90 mg; if taking 90 mg, decr. to 60 mg: combo may incr. brigatinib levels, risk of HTN, bradycardia, other adverse effects; may decr. nilotinib levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• buspirone
Nilceya (nilotinib)

+

buspirone

1 interaction

Avoid/Use Alternative

nilotinib + buspirone

consider alternative or restart buspirone dose at 2.5 mg bid: combo may incr. buspirone levels, risk of adverse effects (hepatic metabolism inhibited)

• butalbital
Nilceya (nilotinib)

+

butalbital

1 interaction

Avoid/Use Alternative

nilotinib + butalbital

avoid combo: combo may decr. nilotinib levels, efficacy (hepatic metabolism induced)

• cabozantinib
Nilceya (nilotinib)

+

cabozantinib

1 interaction

Avoid/Use Alternative

nilotinib + cabozantinib

avoid combo: combo may incr. cabozantinib levels, risk of QT prolongation, cardiac arrhythmias, HTN, GI ulceration, perforation, bleeding (including life-threatening), hypocalcemia, other adverse effects (hepatic metabolism inhibited, additive effects)

• carbamazepine
Nilceya (nilotinib)

+

carbamazepine

1 interaction

Avoid/Use Alternative

nilotinib + carbamazepine

avoid combo: combo may decr. nilotinib levels, efficacy; may incr. carbamazepine levels, risk of hyponatremia, seizures, other adverse effects (hepatic metabolism induced; hepatic metabolism inhibited, additive effects)

• cariprazine
Nilceya (nilotinib)

+

cariprazine

1 interaction

Avoid/Use Alternative

nilotinib + cariprazine

IF STARTING CARIPRAZINE TX: ADULT PTS: adjust dose as follows: SCHIZOPHRENIA/BIPOLAR MANIA: start cariprazine 0.75 mg qd, then may incr. to 1.5 mg qd; BIPOLAR DEPRESSION/DEPRESSION ADJUNCT: start cariprazine 0.75 mg qd; PEDS PTS: avoid combo; IF ON STABLE CARIPRAZINE TX AND STARTING NILOTINIB: ADULT AND PEDS PTS, ALL INDICATIONS: adjust cariprazine dose as follows: if on cariprazine 1.5 mg or 3 mg qd, decr. dose to 0.75 mg qd; if on cariprazine 4.5 mg or 6 mg qd, decr. dose to 1.5 mg qd: combo may incr. cariprazine and active metabolite levels, risk of adverse effects (hepatic metabolism inhibited)

• cenobamate
Nilceya (nilotinib)

+

cenobamate

1 interaction

Avoid/Use Alternative

nilotinib + cenobamate

consider alternative: combo may decr. nilotinib levels, efficacy (hepatic metabolism induced)

• ceritinib
Nilceya (nilotinib)

+

ceritinib

1 interaction

Avoid/Use Alternative

nilotinib + ceritinib

avoid combo: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

• chikungunya vaccine, live
Nilceya (nilotinib)

+

chikungunya vaccine, live

1 interaction

Avoid/Use Alternative

nilotinib + chikungunya vaccine, live

avoid combo; vaccinate at least 4wk before or 3-6mo after nilotinib tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

• chloramphenicol
Nilceya (nilotinib)

+

chloramphenicol

1 interaction

Avoid/Use Alternative

nilotinib + chloramphenicol

use alternative or monitor ECG, CBC; decr. nilotinib dose as follows: newly diagnosed CML: if on nilotinib 300 mg bid, decr. to 200 mg qd; if on nilotinib 142 mg bid, decr. to 95 mg qd; resistant or intolerant CML: if on nilotinib 400 mg bid, decr. to 300 mg qd; if on nilotinib 190 mg bid, decr. to 142 mg qd: combo may incr. nilotinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

• chloroquine
Nilceya (nilotinib)

+

chloroquine

1 interaction

Avoid/Use Alternative

nilotinib + chloroquine

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• cholera vaccine, live
Nilceya (nilotinib)

+

cholera vaccine, live

1 interaction

Avoid/Use Alternative

nilotinib + cholera vaccine, live

avoid combo; vaccinate at least 4wk before or 3-6mo after nilotinib tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

• citalopram
Nilceya (nilotinib)

+

citalopram

1 interaction

Avoid/Use Alternative

nilotinib + citalopram

use alternative or monitor ECG, electrolytes, bleeding s/sx: combo may incr. risk of QT prolongation, cardiac arrhythmias, GI or other bleeding (including life-threatening), hyponatremia (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake)

• cladribine oral
Nilceya (nilotinib)

+

cladribine oral

1 interaction

Avoid/Use Alternative

nilotinib + cladribine oral

use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• clarithromycin
Nilceya (nilotinib)

+

clarithromycin

1 interaction

Avoid/Use Alternative

nilotinib + clarithromycin

avoid combo: combo may incr. nilotinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

• clofazimine
Nilceya (nilotinib)

+

clofazimine

1 interaction

Avoid/Use Alternative

nilotinib + clofazimine

avoid combo: combo may incr. nilotinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

• cobicistat
Nilceya (nilotinib)

+

cobicistat

1 interaction

Avoid/Use Alternative

nilotinib + cobicistat

use alternative or monitor ECG, CBC; decr. nilotinib dose as follows: newly diagnosed CML: if on nilotinib 300 mg bid, decr. to 200 mg qd; if on nilotinib 142 mg bid, decr. to 95 mg qd; resistant or intolerant CML: if on nilotinib 400 mg bid, decr. to 300 mg qd; if on nilotinib 190 mg bid, decr. to 142 mg qd: combo may incr. nilotinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited)

• cobimetinib
Nilceya (nilotinib)

+

cobimetinib

1 interaction

Avoid/Use Alternative

nilotinib + cobimetinib

avoid combo or decr. cobimetinib dose to 20 mg/day and D/C nilotinib w/in 14 days: combo may incr. cobimetinib levels, risk of adverse effects (hepatic metabolism inhibited)

• codeine
Nilceya (nilotinib)

+

codeine

1 interaction

Avoid/Use Alternative

nilotinib + codeine

use alternative or monitor respiratory rate; consider decr. codeine dose: combo may incr. codeine and active metabolite morphine levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited, may incr. production of active metabolite morphine)

• conivaptan
Nilceya (nilotinib)

+

conivaptan

1 interaction

Avoid/Use Alternative

nilotinib + conivaptan

consider alternative or monitor ECG, CBC during and x7 days after conivaptan tx: combo may incr. levels of both drugs, risk of overly rapid serum sodium correction, neurologic sequelae, QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited)

• crizotinib
Nilceya (nilotinib)

+

crizotinib

1 interaction

Avoid/Use Alternative

nilotinib + crizotinib

avoid combo: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, hypokalemia, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

• dabrafenib
Nilceya (nilotinib)

+

dabrafenib

1 interaction

Avoid/Use Alternative

nilotinib + dabrafenib

consider alternative: combo may decr. nilotinib levels, efficacy (hepatic metabolism induced)

• defactinib
Nilceya (nilotinib)

+

defactinib

1 interaction

Avoid/Use Alternative

nilotinib + defactinib

avoid combo: combo may incr. defactinib levels, risk of adverse effects (hepatic metabolism inhibited)

• deferiprone
Nilceya (nilotinib)

+

deferiprone

1 interaction

Avoid/Use Alternative

nilotinib + deferiprone

use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• degarelix
Nilceya (nilotinib)

+

degarelix

1 interaction

Avoid/Use Alternative

nilotinib + degarelix

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• dengue vaccine, live
Nilceya (nilotinib)

+

dengue vaccine, live

1 interaction

Avoid/Use Alternative

nilotinib + dengue vaccine, live

avoid combo; vaccinate at least 4wk before or 3-6mo after nilotinib tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

• desflurane
Nilceya (nilotinib)

+

desflurane

1 interaction

Avoid/Use Alternative

nilotinib + desflurane

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• desipramine
Nilceya (nilotinib)

+

desipramine

1 interaction

Avoid/Use Alternative

nilotinib + desipramine

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias, hyponatremia (additive effects)

• dexlansoprazole
Nilceya (nilotinib)

+

dexlansoprazole

1 interaction

Avoid/Use Alternative

nilotinib + dexlansoprazole

use alternative, incl. H2 blockers 10h before or 2h after nilotinib or short-acting antacids 2h before or 2h after nilotinib: combo may decr. nilotinib levels, efficacy (absorption decreased at higher gastric pH)

• dexmedetomidine
Nilceya (nilotinib)

+

dexmedetomidine

1 interaction

Avoid/Use Alternative

nilotinib + dexmedetomidine

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• dexmedetomidine injection
Nilceya (nilotinib)

+

dexmedetomidine injection

1 interaction

Avoid/Use Alternative

nilotinib + dexmedetomidine injection

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• dexrazoxane
Nilceya (nilotinib)

+

dexrazoxane

1 interaction

Avoid/Use Alternative

nilotinib + dexrazoxane

monitor CBC if anthracycline extravasation or doxorubicin cardioprotective use, otherwise avoid combo: combo may incr. risk of myelosuppression; may decr. efficacy of cancer chemo (additive effects; mechanism unknown)

• dihydrocodeine
Nilceya (nilotinib)

+

dihydrocodeine

1 interaction

Avoid/Use Alternative

nilotinib + dihydrocodeine

use alternative or monitor respiratory rate, consider decr. dihydrocodeine dose: combo may incr. dihydrocodeine and active metabolite dihydromorphine levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited, may incr. production of active metabolite dihydromorphine)

• dihydroergotamine
Nilceya (nilotinib)

+

dihydroergotamine

1 interaction

Avoid/Use Alternative

nilotinib + dihydroergotamine

use alternative: combo may incr. dihydroergotamine levels, risk of ergot toxicity, severe vasospasm, ischemia, other adverse effects (hepatic metabolism inhibited)

• disopyramide
Nilceya (nilotinib)

+

disopyramide

1 interaction

Avoid/Use Alternative

nilotinib + disopyramide

avoid combo: combo may incr. disopyramide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• dofetilide
Nilceya (nilotinib)

+

dofetilide

1 interaction

Avoid/Use Alternative

nilotinib + dofetilide

avoid combo: combo may incr. dofetilide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• donepezil
Nilceya (nilotinib)

+

donepezil

1 interaction

Avoid/Use Alternative

nilotinib + donepezil

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias, GI ulceration, perforation, bleeding, including life-threatening (additive effects)

• dordaviprone
Nilceya (nilotinib)

+

dordaviprone

1 interaction

Avoid/Use Alternative

nilotinib + dordaviprone

avoid combo: combo may incr. dordaviprone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• doxorubicin
Nilceya (nilotinib)

+

doxorubicin

1 interaction

Avoid/Use Alternative

nilotinib + doxorubicin

avoid combo: combo may incr. doxorubicin levels, risk serious infection, myelosuppression, cardiotoxicity, other adverse effects (hepatic metabolism inhibited)

• droperidol
Nilceya (nilotinib)

+

droperidol

1 interaction

Avoid/Use Alternative

nilotinib + droperidol

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• efavirenz
Nilceya (nilotinib)

+

efavirenz

1 interaction

Avoid/Use Alternative

nilotinib + efavirenz

consider alternative: combo may decr. nilotinib levels, efficacy; may incr. risk of QT prolongation, cardiac arrhythmias (hepatic metabolism induced; additive effects)

• elacestrant
Nilceya (nilotinib)

+

elacestrant

1 interaction

Avoid/Use Alternative

nilotinib + elacestrant

avoid combo: combo may incr. elacestrant levels, risk of adverse effects (hepatic metabolism inhibited)

• encorafenib
Nilceya (nilotinib)

+

encorafenib

1 interaction

Avoid/Use Alternative

nilotinib + encorafenib

avoid combo: combo may incr. encorafenib levels, risk of QT prolongation, cardiac arrhythmias, GI or other bleeding (including life-threatening), other adverse effects; may decr. nilotinib levels, efficacy (hepatic metabolism inhibited, additive effects; hepatic metabolism induced)

• ensartinib
Nilceya (nilotinib)

+

ensartinib

1 interaction

Avoid/Use Alternative

nilotinib + ensartinib

avoid combo: combo may incr. ensartinib levels, risk of bradycardia, hyperglycemia, other adverse effects (hepatic metabolism possibly inhibited)

• entrectinib
Nilceya (nilotinib)

+

entrectinib

1 interaction

Avoid/Use Alternative

nilotinib + entrectinib

avoid combo: combo may incr. entrectinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

• enzalutamide
Nilceya (nilotinib)

+

enzalutamide

1 interaction

Avoid/Use Alternative

nilotinib + enzalutamide

avoid combo: combo may decr. nilotinib levels, efficacy (hepatic metabolism induced)

• ephedra
Nilceya (nilotinib)

+

ephedra

1 interaction

Avoid/Use Alternative

nilotinib + ephedra

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• epirubicin
Nilceya (nilotinib)

+

epirubicin

1 interaction

Avoid/Use Alternative

nilotinib + epirubicin

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• erdafitinib
Nilceya (nilotinib)

+

erdafitinib

1 interaction

Avoid/Use Alternative

nilotinib + erdafitinib

avoid combo until after dose titration period at 14-21 days post erdafitinib tx initiation; otherwise, monitor phosphate: combo may interfere with erdafitinib dose titration; may incr. erdafitinib levels, risk of hyperphosphatemia, other adverse effects (altered phosphate levels; hepatic metabolism inhibited)

• ergotamine
Nilceya (nilotinib)

+

ergotamine

1 interaction

Avoid/Use Alternative

nilotinib + ergotamine

use alternative: combo may incr. ergotamine levels, risk of ergot toxicity, severe vasospasm, ischemia, other adverse effects (hepatic metabolism inhibited)

• eribulin
Nilceya (nilotinib)

+

eribulin

1 interaction

Avoid/Use Alternative

nilotinib + eribulin

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• erythromycin
Nilceya (nilotinib)

+

erythromycin

1 interaction

Avoid/Use Alternative

nilotinib + erythromycin

avoid combo: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

• escitalopram
Nilceya (nilotinib)

+

escitalopram

1 interaction

Avoid/Use Alternative

nilotinib + escitalopram

use alternative or monitor ECG, electrolytes, bleeding s/sx: combo may incr. risk of QT prolongation, cardiac arrhythmias, GI or other bleeding (including life-threatening), hyponatremia (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake)

• esomeprazole
Nilceya (nilotinib)

+

esomeprazole

1 interaction

Avoid/Use Alternative

nilotinib + esomeprazole

use alternative, incl. H2 blockers 10h before or 2h after nilotinib or short-acting antacids 2h before or 2h after nilotinib: combo may decr. nilotinib levels, efficacy (absorption decreased at higher gastric pH)

• etrasimod
Nilceya (nilotinib)

+

etrasimod

1 interaction

Avoid/Use Alternative

nilotinib + etrasimod

if CYP2C9 poor metabolizer or if also combined w/ moderate or strong CYP2C9 inhibitor, avoid combo; otherwise, consider alternative or monitor HR, ECG, electrolytes: combo may incr. etrasimod levels, risk of AV block, bradycardia, QT prolongation, cardiac arrhythmias, serious infection, other adverse effects (hepatic metabolism inhibited, additive effects)

• etravirine
Nilceya (nilotinib)

+

etravirine

1 interaction

Avoid/Use Alternative

nilotinib + etravirine

consider alternative: combo may decr. nilotinib levels, efficacy (hepatic metabolism induced)

• fentanyl
Nilceya (nilotinib)

+

fentanyl

1 interaction

Avoid/Use Alternative

nilotinib + fentanyl

use alternative or monitor respiratory rate, consider decr. fentanyl dose: combo may incr. fentanyl levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• fexinidazole
Nilceya (nilotinib)

+

fexinidazole

1 interaction

Avoid/Use Alternative

nilotinib + fexinidazole

avoid combo: combo may decr. nilotinib levels, efficacy; may decr. fexinidazole active metabolite levels, efficacy; may incr. risk of QT prolongation, cardiac arrhythmias, myelosuppression (hepatic metabolism induced; hepatic metabolism inhibited, decr. conversion to active metabolites; additive effects)

• fingolimod
Nilceya (nilotinib)

+

fingolimod

1 interaction

Avoid/Use Alternative

nilotinib + fingolimod

monitor electrolytes, ECG overnight during fingolimod initiation/titration: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• flecainide
Nilceya (nilotinib)

+

flecainide

1 interaction

Avoid/Use Alternative

nilotinib + flecainide

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• fluconazole
Nilceya (nilotinib)

+

fluconazole

1 interaction

Avoid/Use Alternative

nilotinib + fluconazole

use alternative or monitor ECG, electrolytes, CBC: combo may incr. nilotinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

• fluorouracil
Nilceya (nilotinib)

+

fluorouracil

1 interaction

Avoid/Use Alternative

nilotinib + fluorouracil

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• fluoxetine
Nilceya (nilotinib)

+

fluoxetine

1 interaction

Avoid/Use Alternative

nilotinib + fluoxetine

use alternative or monitor ECG, electrolytes, bleeding s/sx: combo may incr. risk of QT prolongation, cardiac arrhythmias, hyponatremia, GI or other bleeding, including life-threatening (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake)

• fosaprepitant
Nilceya (nilotinib)

+

fosaprepitant

1 interaction

Avoid/Use Alternative

nilotinib + fosaprepitant

avoid combo: combo may incr. aprepitant levels, risk of adverse effects (hepatic metabolism inhibited)

• foscarnet
Nilceya (nilotinib)

+

foscarnet

1 interaction

Avoid/Use Alternative

nilotinib + foscarnet

use alternative or monitor ECG, electrolytes, CBC: combo may incr. risk of severe hypocalcemia, hypokalemia, QT prolongation, cardiac arrhythmias, tetany, seizures, myelosuppression (additive effects)

• fosfomycin injection
Nilceya (nilotinib)

+

fosfomycin injection

1 interaction

Avoid/Use Alternative

nilotinib + fosfomycin injection

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias, myelosuppression, hypocalcemia, hypokalemia (additive effects)

• fosphenytoin
Nilceya (nilotinib)

+

fosphenytoin

1 interaction

Avoid/Use Alternative

nilotinib + fosphenytoin

avoid combo: combo may decr. nilotinib levels, efficacy (hepatic metabolism induced)

• ganciclovir
Nilceya (nilotinib)

+

ganciclovir

1 interaction

Avoid/Use Alternative

nilotinib + ganciclovir

use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• gemtuzumab ozogamicin
Nilceya (nilotinib)

+

gemtuzumab ozogamicin

1 interaction

Avoid/Use Alternative

nilotinib + gemtuzumab ozogamicin

monitor ECG, electrolytes, platelets, bleeding s/sx: combo may incr. risk of QT prolongation, cardiac arrhythmias, GI or other bleeding, including life-threatening (additive effects)

• gepotidacin
Nilceya (nilotinib)

+

gepotidacin

1 interaction

Avoid/Use Alternative

nilotinib + gepotidacin

use alternative or monitor ECG, electrolytes: combo may incr. gepotidacin levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• gilteritinib
Nilceya (nilotinib)

+

gilteritinib

1 interaction

Avoid/Use Alternative

nilotinib + gilteritinib

avoid combo: combo may incr. gilteritinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• givinostat
Nilceya (nilotinib)

+

givinostat

1 interaction

Avoid/Use Alternative

nilotinib + givinostat

use alternative or monitor CBC, ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias, myelosuppression (additive effects)

• glasdegib
Nilceya (nilotinib)

+

glasdegib

1 interaction

Avoid/Use Alternative

nilotinib + glasdegib

avoid combo: combo may incr. glasdegib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

• goserelin
Nilceya (nilotinib)

+

goserelin

1 interaction

Avoid/Use Alternative

nilotinib + goserelin

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• grapefruit
Nilceya (nilotinib)

+

grapefruit

1 interaction

Avoid/Use Alternative

nilotinib + grapefruit

avoid grapefruit juice: combo may incr. nilotinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (GI metabolism inhibited, additive effects)

• haloperidol
Nilceya (nilotinib)

+

haloperidol

1 interaction

Avoid/Use Alternative

nilotinib + haloperidol

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• histrelin
Nilceya (nilotinib)

+

histrelin

1 interaction

Avoid/Use Alternative

nilotinib + histrelin

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• hydrocodone
Nilceya (nilotinib)

+

hydrocodone

1 interaction

Avoid/Use Alternative

nilotinib + hydrocodone

use alternative or monitor respiratory rate, ECG, electrolytes, especially if hydrocodone ER doses >160 mg/day; consider decr. (benz)hydrocodone dose: combo may incr. hydrocodone levels, risk of CNS and respiratory depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• hydroxychloroquine
Nilceya (nilotinib)

+

hydroxychloroquine

1 interaction

Avoid/Use Alternative

nilotinib + hydroxychloroquine

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias, myelosuppression (additive effects)

• hydroxyzine
Nilceya (nilotinib)

+

hydroxyzine

1 interaction

Avoid/Use Alternative

nilotinib + hydroxyzine

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ibutilide
Nilceya (nilotinib)

+

ibutilide

1 interaction

Avoid/Use Alternative

nilotinib + ibutilide

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• idelalisib
Nilceya (nilotinib)

+

idelalisib

1 interaction

Avoid/Use Alternative

nilotinib + idelalisib

use alternative or monitor ECG, CBC; decr. nilotinib dose as follows: newly diagnosed CML: if on nilotinib 300 mg bid, decr. to 200 mg qd; if on nilotinib 142 mg bid, decr. to 95 mg qd; resistant or intolerant CML: if on nilotinib 400 mg bid, decr. to 300 mg qd; if on nilotinib 190 mg bid, decr. to 142 mg qd: combo may incr. nilotinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited)

• iloperidone
Nilceya (nilotinib)

+

iloperidone

1 interaction

Avoid/Use Alternative

nilotinib + iloperidone

use alternative or monitor ECG, electrolytes: combo may incr. iloperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• influenza nasal vaccine, live
Nilceya (nilotinib)

+

influenza nasal vaccine, live

1 interaction

Avoid/Use Alternative

nilotinib + influenza nasal vaccine, live

avoid combo; vaccinate at least 4wk before or 3-6mo after nilotinib tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

• inotuzumab ozogamicin
Nilceya (nilotinib)

+

inotuzumab ozogamicin

1 interaction

Avoid/Use Alternative

nilotinib + inotuzumab ozogamicin

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• isoflurane
Nilceya (nilotinib)

+

isoflurane

1 interaction

Avoid/Use Alternative

nilotinib + isoflurane

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• itraconazole
Nilceya (nilotinib)

+

itraconazole

1 interaction

Avoid/Use Alternative

nilotinib + itraconazole

use alternative or monitor ECG, CBC and decr. nilotinib dose as follows during and x2wk after itraconazole tx: newly diagnosed CML: if on nilotinib 300 mg bid, decr. to 200 mg qd; if on nilotinib 142 mg bid, decr. to 95 mg qd; resistant or intolerant CML: if on nilotinib 400 mg bid, decr. to 300 mg qd; if on nilotinib 190 mg bid, decr. to 142 mg qd; consider decr itraconazole dose: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited)

• ivabradine
Nilceya (nilotinib)

+

ivabradine

1 interaction

Avoid/Use Alternative

nilotinib + ivabradine

avoid combo: combo may incr. ivabradine levels, risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• ivacaftor
Nilceya (nilotinib)

+

ivacaftor

1 interaction

Avoid/Use Alternative

nilotinib + ivacaftor

pts <6 mo: avoid combo; pts >6 mo decr. ivacaftor dose as follows: 6 mo-5 yo and 5-6.9 kg: give 25 mg qd; 6 mo-5 yo and 7-13.9 kg: give 50 mg qd; 6 mo-5 yo and >14 kg: give 75 mg qd; 6 yo and older: give 150 mg qd: combo may incr. ivacaftor levels, risk of adverse effects (hepatic metabolism inhibited)

• ivosidenib
Nilceya (nilotinib)

+

ivosidenib

1 interaction

Avoid/Use Alternative

nilotinib + ivosidenib

avoid combo: combo may incr. ivosidenib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects; may decr. nilotinib levels, efficacy (hepatic metabolism inhibited, additive effects; hepatic metabolism induced)

• ixabepilone
Nilceya (nilotinib)

+

ixabepilone

1 interaction

Avoid/Use Alternative

nilotinib + ixabepilone

consider alternatives or monitor CBC: combo may incr. ixabepilone levels, risk of serious infection, myelosuppression, other toxicity (hepatic metabolism inhibited)

• ketoconazole
Nilceya (nilotinib)

+

ketoconazole

1 interaction

Avoid/Use Alternative

nilotinib + ketoconazole

use alternative or monitor ECG, CBC and decr. nilotinib dose as follows during and up to 1wk after ketoconazole tx: newly diagnosed CML: if on nilotinib 300 mg bid, decr. to 200 mg qd; if on nilotinib 142 mg bid, decr. to 95 mg qd; resistant or intolerant CML: if on nilotinib 400 mg bid, decr. to 300 mg qd; if on nilotinib 190 mg bid, decr. to 142 mg qd: combo may incr. nilotinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited)

• lansoprazole
Nilceya (nilotinib)

+

lansoprazole

1 interaction

Avoid/Use Alternative

nilotinib + lansoprazole

use alternative, incl. H2 blockers 10h before or 2h after nilotinib or short-acting antacids 2h before or 2h after nilotinib: combo may decr. nilotinib levels, efficacy (absorption decreased at higher gastric pH)

• lefamulin
Nilceya (nilotinib)

+

lefamulin

1 interaction

Avoid/Use Alternative

nilotinib + lefamulin

avoid combo: combo with oral lefamulin may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects; combo with IV lefamulin may incr. risk of QT prolongation, cardiac arrhythmias (hepatic metabolism inhibited, additive effects)

• lemborexant
Nilceya (nilotinib)

+

lemborexant

1 interaction

Avoid/Use Alternative

nilotinib + lemborexant

avoid combo: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• leuprolide
Nilceya (nilotinib)

+

leuprolide

1 interaction

Avoid/Use Alternative

nilotinib + leuprolide

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• levofloxacin
Nilceya (nilotinib)

+

levofloxacin

1 interaction

Avoid/Use Alternative

nilotinib + levofloxacin

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• lisinopril
Nilceya (nilotinib)

+

lisinopril

1 interaction

Avoid/Use Alternative

nilotinib + lisinopril

consider alternative or monitor potassium: combo may incr. risk of hyperkalemia (additive effects)

• lofexidine
Nilceya (nilotinib)

+

lofexidine

1 interaction

Avoid/Use Alternative

nilotinib + lofexidine

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• lonafarnib
Nilceya (nilotinib)

+

lonafarnib

1 interaction

Avoid/Use Alternative

nilotinib + lonafarnib

avoid combo: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

• loperamide
Nilceya (nilotinib)

+

loperamide

1 interaction

Avoid/Use Alternative

nilotinib + loperamide

use alternative or monitor ECG, electrolytes, esp. if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• lopinavir/ritonavir
Nilceya (nilotinib)

+

lopinavir/ ritonavir

1 interaction

Avoid/Use Alternative

nilotinib + lopinavir/ ritonavir

use alternative or monitor ECG, electrolytes, CBC; decr. nilotinib dose as follows: newly diagnosed CML: if on nilotinib 300 mg bid, decr. to 200 mg qd; if on nilotinib 142 mg bid, decr. to 95 mg qd; resistant or intolerant CML: if on nilotinib 400 mg bid, decr. to 300 mg qd; if on nilotinib 190 mg bid, decr. to 142 mg qd: combo may incr. nilotinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

• lorlatinib
Nilceya (nilotinib)

+

lorlatinib

1 interaction

Avoid/Use Alternative

nilotinib + lorlatinib

consider alternative: combo may decr. nilotinib levels, efficacy (hepatic metabolism induced)

• lovastatin
Nilceya (nilotinib)

+

lovastatin

1 interaction

Avoid/Use Alternative

nilotinib + lovastatin

use alternative or monitor CK, myopathy sx; adjust lovastatin max dose to 20 mg/day: combo may incr. lovastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic metabolism inhibited)

• lumacaftor/ivacaftor
Nilceya (nilotinib)

+

lumacaftor/ ivacaftor

1 interaction

Avoid/Use Alternative

nilotinib + lumacaftor/ ivacaftor

avoid combo: combo may decr. nilotinib levels, efficacy; may incr. ivacaftor levels, risk of adverse effects (hepatic metabolism induced; hepatic metabolism inhibited)

• lurbinectedin
Nilceya (nilotinib)

+

lurbinectedin

1 interaction

Avoid/Use Alternative

nilotinib + lurbinectedin

use alternative or monitor CBC; decr. lurbinectedin dose 50%: combo may incr. lurbinectedin levels, risk of myelosuppression, other adverse effects (hepatic metabolism inhibited)

• macimorelin
Nilceya (nilotinib)

+

macimorelin

1 interaction

Avoid/Use Alternative

nilotinib + macimorelin

avoid combo, allowing sufficient washout time before diagnostic test: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• macitentan
Nilceya (nilotinib)

+

macitentan

1 interaction

Avoid/Use Alternative

nilotinib + macitentan

if also combined w/ strong-mod CYP2C9 inhibitor, avoid combo; otherwise, caution advised: combo may incr. macitentan levels, risk of adverse effects (hepatic metabolism inhibited)

• mavacamten
Nilceya (nilotinib)

+

mavacamten

1 interaction

Avoid/Use Alternative

nilotinib + mavacamten

consider alternative or monitor cardiac fxn, incl. LVEF; if patient stable on nilotinib tx, initiate mavacamten at 5 mg qd; if adding short-term (<1wk) nilotinib tx to existing mavacamten tx, hold mavacamten until nilotinib D/C; if adding longer-term (>1wk) nilotinib tx, decr. mavacamten dose as follows for at least 12wk: decr. mavacamten 15 mg qd to 10 mg qd; decr. mavacamten 10 mg qd to 5 mg qd; decr. mavacamten 5 mg qd to 2.5 mg qd; do not start nilotinib tx if on mavacamten 2.5 mg qd: combo may incr. mavacamten levels, risk of heart failure, other adverse effects; may decr. nilotinib levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• measles/mumps/rubella vaccine, live
Nilceya (nilotinib)

+

measles/ mumps/ rubella vaccine, live

1 interaction

Avoid/Use Alternative

nilotinib + measles/ mumps/ rubella vaccine, live

avoid combo; vaccinate at least 4wk before or 3-6mo after nilotinib tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

• meperidine
Nilceya (nilotinib)

+

meperidine

1 interaction

Avoid/Use Alternative

nilotinib + meperidine

use alternative or monitor respiratory rate, ECG, electrolytes; consider decr. meperidine dose: combo may incr. meperidine levels, risk of CNS and respiratory depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• methadone
Nilceya (nilotinib)

+

methadone

1 interaction

Avoid/Use Alternative

nilotinib + methadone

avoid combo: combo may incr. methadone levels, risk of CNS and respiratory depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• methylergonovine
Nilceya (nilotinib)

+

methylergonovine

1 interaction

Avoid/Use Alternative

nilotinib + methylergonovine

avoid combo: combo may incr. methylergonovine levels, risk of ergot toxicity, severe vasospasm, ischemia, other adverse effects (hepatic metabolism inhibited)

• midazolam
Nilceya (nilotinib)

+

midazolam

1 interaction

Avoid/Use Alternative

nilotinib + midazolam

avoid combo if midazolam nasal use; otherwise, monitor respiratory rate, consider decr. midazolam dose: combo may incr. midazolam and active metabolite levels, risk of profound CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• mifepristone
Nilceya (nilotinib)

+

mifepristone

1 interaction

Avoid/Use Alternative

nilotinib + mifepristone

use alternative or monitor ECG, electrolytes, CBC, decr. nilotinib dose as follows during and 14 days after daily mifepristone use: newly diagnosed CML: if on nilotinib 300 mg bid, decr. to 200 mg qd; if on nilotinib 142 mg bid, decr. to 95 mg qd; resistant or intolerant CML: if on nilotinib 400 mg bid, decr. to 300 mg qd; if on nilotinib 190 mg bid, decr. to 142 mg qd; caution advised if pregnancy termination use: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, myelosuppression, hypokalemia, other adverse effects (hepatic metabolism inhibited, additive effects)

• milsaperidone
Nilceya (nilotinib)

+

milsaperidone

1 interaction

Avoid/Use Alternative

nilotinib + milsaperidone

use alternative or monitor ECG, electrolytes: combo may incr. milsaperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• mitapivat
Nilceya (nilotinib)

+

mitapivat

1 interaction

Avoid/Use Alternative

nilotinib + mitapivat

THALASSEMIA: avoid combo; HEMOLYTIC ANEMIA: consider alternative or monitor Hgb; adjust max mitapivat dose to 20 mg bid: combo may incr. mitapivat levels, risk of adverse effects; may decr. nilotinib levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• mitotane
Nilceya (nilotinib)

+

mitotane

1 interaction

Avoid/Use Alternative

nilotinib + mitotane

avoid combo: combo may decr. nilotinib levels, efficacy; may incr. risk of GI or other bleeding, including life-threatening (hepatic metabolism induced; additive effects)

• mobocertinib
Nilceya (nilotinib)

+

mobocertinib

1 interaction

Avoid/Use Alternative

nilotinib + mobocertinib

avoid combo: combo may incr. mobocertinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects; may decr. nilotinib levels, efficacy (hepatic metabolism inhibited, additive effects; hepatic metabolism induced)

• modafinil
Nilceya (nilotinib)

+

modafinil

1 interaction

Avoid/Use Alternative

nilotinib + modafinil

consider alternative: combo may decr. nilotinib levels, efficacy (hepatic metabolism induced)

• moxifloxacin
Nilceya (nilotinib)

+

moxifloxacin

1 interaction

Avoid/Use Alternative

nilotinib + moxifloxacin

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• nafcillin
Nilceya (nilotinib)

+

nafcillin

1 interaction

Avoid/Use Alternative

nilotinib + nafcillin

consider alternative: combo may decr. nilotinib levels, efficacy (hepatic metabolism induced)

• naloxegol
Nilceya (nilotinib)

+

naloxegol

1 interaction

Avoid/Use Alternative

nilotinib + naloxegol

avoid combo or decr. naloxegol dose to 12.5 mg/day: combo may incr. naloxegol levels, risk of adverse effects (hepatic metabolism inhibited)

• nefazodone
Nilceya (nilotinib)

+

nefazodone

1 interaction

Avoid/Use Alternative

nilotinib + nefazodone

use alternative or monitor ECG, CBC; decr. nilotinib dose as follows: newly diagnosed CML: if on nilotinib 300 mg bid, decr. to 200 mg qd; if on nilotinib 142 mg bid, decr. to 95 mg qd; resistant or intolerant CML: if on nilotinib 400 mg bid, decr. to 300 mg qd; if on nilotinib 190 mg bid, decr. to 142 mg qd: combo may incr. nilotinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited)

• nelfinavir
Nilceya (nilotinib)

+

nelfinavir

1 interaction

Avoid/Use Alternative

nilotinib + nelfinavir

use alternative or monitor ECG, CBC; decr. nilotinib dose as follows: newly diagnosed CML: if on nilotinib 300 mg bid, decr. to 200 mg qd; if on nilotinib 142 mg bid, decr. to 95 mg qd; resistant or intolerant CML: if on nilotinib 400 mg bid, decr. to 300 mg qd; if on nilotinib 190 mg bid, decr. to 142 mg qd: combo may incr. nilotinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited)

• neratinib
Nilceya (nilotinib)

+

neratinib

1 interaction

Avoid/Use Alternative

nilotinib + neratinib

avoid combo if also combined w/ P-gp inhibitor; otherwise, caution advised: combo may incr. neratinib levels, risk of adverse effects (hepatic metabolism inhibited)

• nirogacestat
Nilceya (nilotinib)

+

nirogacestat

1 interaction

Avoid/Use Alternative

nilotinib + nirogacestat

avoid combo: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, myelosuppression, hypophosphatemia, other adverse effects (hepatic metabolism inhibited)

• nisoldipine
Nilceya (nilotinib)

+

nisoldipine

1 interaction

Avoid/Use Alternative

nilotinib + nisoldipine

consider alternative or monitor BP: combo may incr. nisoldipine levels, risk of hypotension, other adverse effects (hepatic metabolism inhibited)

• olaparib
Nilceya (nilotinib)

+

olaparib

1 interaction

Avoid/Use Alternative

nilotinib + olaparib

use alternative or monitor CBC; decr. olaparib dose to 150 mg bid: combo may incr. olaparib levels, risk of myelosuppression, other adverse effects (hepatic metabolism inhibited)

• oliceridine
Nilceya (nilotinib)

+

oliceridine

1 interaction

Avoid/Use Alternative

nilotinib + oliceridine

avoid combo: combo may incr. oliceridine levels, risk of CNS and respiratory depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• olmesartan medoxomil
Nilceya (nilotinib)

+

olmesartan medoxomil

1 interaction

Avoid/Use Alternative

nilotinib + olmesartan medoxomil

consider alternative or monitor potassium: combo may incr. risk of hyperkalemia (additive effects)

• omaveloxolone
Nilceya (nilotinib)

+

omaveloxolone

1 interaction

Avoid/Use Alternative

nilotinib + omaveloxolone

use alternative or decr. omaveloxolone dose to 100 mg/day: combo may incr. omaveloxolone levels, risk of adverse effects; may decr. nilotinib levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• omeprazole
Nilceya (nilotinib)

+

omeprazole

1 interaction

Avoid/Use Alternative

nilotinib + omeprazole

use alternative, incl. H2 blockers 10h before or 2h after nilotinib or short-acting antacids 2h before or 2h after nilotinib: combo may decr. nilotinib levels, efficacy (absorption decreased at higher gastric pH)

• ondansetron
Nilceya (nilotinib)

+

ondansetron

1 interaction

Avoid/Use Alternative

nilotinib + ondansetron

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• osimertinib
Nilceya (nilotinib)

+

osimertinib

1 interaction

Avoid/Use Alternative

nilotinib + osimertinib

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• oxaliplatin
Nilceya (nilotinib)

+

oxaliplatin

1 interaction

Avoid/Use Alternative

nilotinib + oxaliplatin

use alternative or monitor ECG, electrolytes, bleeding s/sx: combo may incr. risk of QT prolongation, cardiac arrhythmias, GI or other bleeding, including life-threatening (additive effects)

• oxycodone
Nilceya (nilotinib)

+

oxycodone

1 interaction

Avoid/Use Alternative

nilotinib + oxycodone

use alternative or monitor respiratory rate; consider decr. oxycodone dose: combo may incr. oxycodone levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• ozanimod
Nilceya (nilotinib)

+

ozanimod

1 interaction

Avoid/Use Alternative

nilotinib + ozanimod

consider alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• pacritinib
Nilceya (nilotinib)

+

pacritinib

1 interaction

Avoid/Use Alternative

nilotinib + pacritinib

avoid combo: combo may incr. pacritinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, GI or other bleeding (including life-threatening), other adverse effects; may decr. nilotinib levels, efficacy (hepatic metabolism inhibited, additive effects; hepatic metabolism induced)

• palifermin
Nilceya (nilotinib)

+

palifermin

1 interaction

Avoid/Use Alternative

nilotinib + palifermin

avoid palifermin admin. w/in 24h before, during tx, or w/in 24h after myelotoxic chemo; otherwise, caution advised: combo may incr. severity and duration of oral mucositis (antagonistic effects)

• paliperidone
Nilceya (nilotinib)

+

paliperidone

1 interaction

Avoid/Use Alternative

nilotinib + paliperidone

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• palonosetron
Nilceya (nilotinib)

+

palonosetron

1 interaction

Avoid/Use Alternative

nilotinib + palonosetron

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• palovarotene
Nilceya (nilotinib)

+

palovarotene

1 interaction

Avoid/Use Alternative

nilotinib + palovarotene

use alternative or decr. palovarotene dose as follows: wt 10-19.9 kg maint. dose 1 mg daily, flare dose 5 mg daily wk 1-4, then 2.5 mg daily wk 5-12; wt 20-39.9 kg maint. dose 1.5 mg daily, flare dose 6 mg daily wk 1-4, then 3 mg daily wk 5-12; wt 40-59.9 kg maint. dose 2 mg daily, flare dose 7.5 mg daily wk 1-4, then 4 mg daily wk 5-12; wt 60 kg and greater or 14 yo and older maint. dose 2.5 mg daily, flare dose 10 mg daily wk 1-4, then 5 mg daily wk 5-12: combo may incr. palovarotene levels, risk of adverse effects (hepatic metabolism inhibited)

• pantoprazole
Nilceya (nilotinib)

+

pantoprazole

1 interaction

Avoid/Use Alternative

nilotinib + pantoprazole

use alternative, incl. H2 blockers 10h before or 2h after nilotinib or short-acting antacids 2h before or 2h after nilotinib: combo may decr. nilotinib levels, efficacy (absorption decreased at higher gastric pH)

• pasireotide
Nilceya (nilotinib)

+

pasireotide

1 interaction

Avoid/Use Alternative

nilotinib + pasireotide

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• pazopanib
Nilceya (nilotinib)

+

pazopanib

1 interaction

Avoid/Use Alternative

nilotinib + pazopanib

avoid combo: combo may incr. pazopanib levels, risk of QT prolongation, cardiac arrhythmias, GI ulceration, perforation, bleeding (including life-threatening), other adverse effects (hepatic metabolism inhibited, additive effects)

• pemigatinib
Nilceya (nilotinib)

+

pemigatinib

1 interaction

Avoid/Use Alternative

nilotinib + pemigatinib

use alternative or monitor phosphate and decr. pemigatinib dose as follows: if on pemigatinib 13.5 mg qd, decr. to 9 mg qd; if on pemigatinib 9 mg qd, decr. to 4.5 mg qd: combo may incr. pemigatinib levels, risk of hyperphosphatemia, other adverse effects (hepatic metabolism inhibited)

• penicillamine
Nilceya (nilotinib)

+

penicillamine

1 interaction

Avoid/Use Alternative

nilotinib + penicillamine

use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• pentamidine
Nilceya (nilotinib)

+

pentamidine

1 interaction

Avoid/Use Alternative

nilotinib + pentamidine

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias, myelosuppression, hypocalcemia (additive effects)

• pentobarbital
Nilceya (nilotinib)

+

pentobarbital

1 interaction

Avoid/Use Alternative

nilotinib + pentobarbital

avoid combo: combo may decr. nilotinib levels, efficacy (hepatic metabolism induced)

• perindopril
Nilceya (nilotinib)

+

perindopril

1 interaction

Avoid/Use Alternative

nilotinib + perindopril

consider alternative or monitor potassium: combo may incr. risk of hyperkalemia (additive effects)

• pexidartinib
Nilceya (nilotinib)

+

pexidartinib

1 interaction

Avoid/Use Alternative

nilotinib + pexidartinib

consider alternative: combo may incr. pexidartinib levels, risk of hepatotoxicity, other adverse effects; may decr. nilotinib levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• phenobarbital
Nilceya (nilotinib)

+

phenobarbital

1 interaction

Avoid/Use Alternative

nilotinib + phenobarbital

avoid combo: combo may decr. nilotinib levels, efficacy; may incr. risk of QT prolongation, cardiac arrhythmias (hepatic metabolism induced; additive effects)

• phenytoin
Nilceya (nilotinib)

+

phenytoin

1 interaction

Avoid/Use Alternative

nilotinib + phenytoin

avoid combo: combo may decr. nilotinib levels, efficacy (hepatic metabolism induced)

• pimavanserin
Nilceya (nilotinib)

+

pimavanserin

1 interaction

Avoid/Use Alternative

nilotinib + pimavanserin

avoid combo: combo may incr. pimavanserin levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• pitolisant
Nilceya (nilotinib)

+

pitolisant

1 interaction

Avoid/Use Alternative

nilotinib + pitolisant

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ponesimod
Nilceya (nilotinib)

+

ponesimod

1 interaction

Avoid/Use Alternative

nilotinib + ponesimod

use alternative or monitor HR, ECG, electrolytes: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (additive effects)

• potassium chloride
Nilceya (nilotinib)

+

potassium chloride

1 interaction

Avoid/Use Alternative

nilotinib + potassium chloride

IV potassium chloride: use alternative or monitor potassium, ECG; ORAL potassium: monitor potassium, ECG: combo may incr. risk of severe hyperkalemia, cardiac arrest (additive effects)

• potassium phosphate
Nilceya (nilotinib)

+

potassium phosphate

1 interaction

Avoid/Use Alternative

nilotinib + potassium phosphate

use alternative or monitor potassium, ECG: combo may incr. risk of severe hyperkalemia, cardiac arrest (additive effects)

• pralsetinib
Nilceya (nilotinib)

+

pralsetinib

1 interaction

Avoid/Use Alternative

nilotinib + pralsetinib

use alternative or monitor ECG, calcium, bleeding s/sx, consider monitoring other electrolytes and decr. pralsetinib dose as follows: if on pralsetinib 400 mg qd, decr. to 300 mg qd; if on pralsetinib 300 mg qd, decr. to 200 mg qd; if on pralsetinib 200 mg qd, decr. to 100 mg qd: combo may incr. pralsetinib levels, risk of QT prolongation, cardiac arrhythmias, hypocalcemia, GI or other bleeding (including life-threatening), other adverse effects (hepatic metabolism inhibited, additive effects)

• primaquine
Nilceya (nilotinib)

+

primaquine

1 interaction

Avoid/Use Alternative

nilotinib + primaquine

use alternative or monitor ECG, electrolytes, CBC: combo may incr. risk of QT prolongation, cardiac arrhythmias, myelosuppression (additive effects)

• primidone
Nilceya (nilotinib)

+

primidone

1 interaction

Avoid/Use Alternative

nilotinib + primidone

avoid combo: combo may decr. nilotinib levels, efficacy (hepatic metabolism induced)

• procainamide
Nilceya (nilotinib)

+

procainamide

1 interaction

Avoid/Use Alternative

nilotinib + procainamide

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• propafenone
Nilceya (nilotinib)

+

propafenone

1 interaction

Avoid/Use Alternative

nilotinib + propafenone

avoid combo: combo may incr. propafenone levels, risk of QT prolongation, cardiac arrhythmias, hypotension, other adverse effects (hepatic metabolism inhibited, additive effects)

• quetiapine
Nilceya (nilotinib)

+

quetiapine

1 interaction

Avoid/Use Alternative

nilotinib + quetiapine

use alternative or monitor ECG, electrolytes; consider decr. quetiapine dose: combo may incr. quetiapine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• quinidine (antiarrhythmic)
Nilceya (nilotinib)

+

quinidine (antiarrhythmic)

1 interaction

Avoid/Use Alternative

nilotinib + quinidine (antiarrhythmic)

avoid combo: combo may incr. quinidine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• quinidine (CYP2D6 inhibitor)
Nilceya (nilotinib)

+

quinidine (CYP2D6 inhibitor)

1 interaction

Avoid/Use Alternative

nilotinib + quinidine (CYP2D6 inhibitor)

avoid combo: combo may incr. quinidine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• quinine
Nilceya (nilotinib)

+

quinine

1 interaction

Avoid/Use Alternative

nilotinib + quinine

avoid combo: combo may incr. quinine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• quizartinib
Nilceya (nilotinib)

+

quizartinib

1 interaction

Avoid/Use Alternative

nilotinib + quizartinib

avoid combo: combo may incr. quizartinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• rabeprazole
Nilceya (nilotinib)

+

rabeprazole

1 interaction

Avoid/Use Alternative

nilotinib + rabeprazole

use alternative, incl. H2 blockers 10h before or 2h after nilotinib or short-acting antacids 2h before or 2h after nilotinib: combo may decr. nilotinib levels, efficacy (absorption decreased at higher gastric pH)

• rabies vaccine
Nilceya (nilotinib)

+

rabies vaccine

1 interaction

Avoid/Use Alternative

nilotinib + rabies vaccine

if possible, avoid immunosuppressive tx or vaccinate at least 2wk before starting nilotinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• radium Ra 223 dichloride
Nilceya (nilotinib)

+

radium Ra 223 dichloride

1 interaction

Avoid/Use Alternative

nilotinib + radium Ra 223 dichloride

use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• remibrutinib
Nilceya (nilotinib)

+

remibrutinib

1 interaction

Avoid/Use Alternative

nilotinib + remibrutinib

avoid combo: combo may incr. remibrutinib levels, risk of GI or other bleeding (including life-threatening), other adverse effects (hepatic metabolism inhibited, additive effects)

• repotrectinib
Nilceya (nilotinib)

+

repotrectinib

1 interaction

Avoid/Use Alternative

nilotinib + repotrectinib

avoid combo; D/C nilotinib 3-5 half-lives prior to repotrectinib tx: combo may incr. repotrectinib levels, risk of adverse effects; may decr. nilotinib levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• revumenib
Nilceya (nilotinib)

+

revumenib

1 interaction

Avoid/Use Alternative

nilotinib + revumenib

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ribociclib
Nilceya (nilotinib)

+

ribociclib

1 interaction

Avoid/Use Alternative

nilotinib + ribociclib

avoid combo: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

• rifabutin
Nilceya (nilotinib)

+

rifabutin

1 interaction

Avoid/Use Alternative

nilotinib + rifabutin

avoid combo: combo may incr. rifabutin levels, risk of myelosuppression, uveitis, other adverse effects; may decr. nilotinib levels, efficacy (hepatic metabolism inhibited, additive effects; hepatic metabolism induced)

• rifampin
Nilceya (nilotinib)

+

rifampin

1 interaction

Avoid/Use Alternative

nilotinib + rifampin

avoid combo: combo may decr. nilotinib levels, efficacy (hepatic metabolism induced)

• rifapentine
Nilceya (nilotinib)

+

rifapentine

1 interaction

Avoid/Use Alternative

nilotinib + rifapentine

consider alternative: combo may decr. nilotinib levels, efficacy (hepatic metabolism induced)

• rilpivirine
Nilceya (nilotinib)

+

rilpivirine

1 interaction

Avoid/Use Alternative

nilotinib + rilpivirine

consider alternative or monitor ECG, electrolytes; risk may be lower w/ IM rilpivirine: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• rilzabrutinib
Nilceya (nilotinib)

+

rilzabrutinib

1 interaction

Avoid/Use Alternative

nilotinib + rilzabrutinib

avoid combo if nilotinib use greater than 7 days; use alternative or hold rilzabrutinib if nilotinib use less than 7 days: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited)

• ritonavir
Nilceya (nilotinib)

+

ritonavir

1 interaction

Avoid/Use Alternative

nilotinib + ritonavir

use alternative or monitor ECG, CBC; decr. nilotinib dose as follows: newly diagnosed CML: if on nilotinib 300 mg bid, decr. to 200 mg qd; if on nilotinib 142 mg bid, decr. to 95 mg qd; resistant or intolerant CML: if on nilotinib 400 mg bid, decr. to 300 mg qd; if on nilotinib 190 mg bid, decr. to 142 mg qd: combo may incr. nilotinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited)

• rivaroxaban
Nilceya (nilotinib)

+

rivaroxaban

1 interaction

Avoid/Use Alternative

nilotinib + rivaroxaban

use alternative if CrCl <80 and combined w/ P-gp inhibitor; otherwise, monitor bleeding s/sx: combo may incr. rivaroxaban levels, risk of GI or other bleeding (including life-threatening), other adverse effects (hepatic metabolism inhibited, additive effects)

• romidepsin
Nilceya (nilotinib)

+

romidepsin

1 interaction

Avoid/Use Alternative

nilotinib + romidepsin

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias, hypocalcemia, hyponatremia (additive effects)

• ropeginterferon alfa-2b
Nilceya (nilotinib)

+

ropeginterferon alfa-2b

1 interaction

Avoid/Use Alternative

nilotinib + ropeginterferon alfa-2b

use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• rotavirus vaccine, live
Nilceya (nilotinib)

+

rotavirus vaccine, live

1 interaction

Avoid/Use Alternative

nilotinib + rotavirus vaccine, live

avoid combo; vaccinate at least 4wk before or 3-6mo after nilotinib tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

• rucaparib
Nilceya (nilotinib)

+

rucaparib

1 interaction

Avoid/Use Alternative

nilotinib + rucaparib

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• selpercatinib
Nilceya (nilotinib)

+

selpercatinib

1 interaction

Avoid/Use Alternative

nilotinib + selpercatinib

use alternative or monitor ECG, electrolytes, bleeding s/sx; decr. selpercatinib dose as follows: if on selpercatinib 40 mg tid, decr. to 40 mg qd; if on selpercatinib 80 mg bid, decr. to 40 mg bid; if on selpercatinib 120 mg bid, decr. to 80 mg bid; if on selpercatinib 160 mg bid, decr. to 120 mg bid: combo may incr. selpercatinib levels, risk of QT prolongation, cardiac arrhythmias, GI or other bleeding (including life-threatening), other adverse effects (hepatic metabolism inhibited, additive effects)

• selumetinib
Nilceya (nilotinib)

+

selumetinib

1 interaction

Avoid/Use Alternative

nilotinib + selumetinib

use alternative or monitor LVEF, CK, myopathy sx, bleeding s/sx; decr. selumetinib dose as follows: if on selumetinib 25 mg/m^2 bid, decr. to 20 mg/m^2 bid; if on selumetinib 20 mg/m^2 bid, decr. to 15 mg/m^2 bid; see selumetinib pkg insert for specific dose adjustments: combo may incr. selumetinib levels, risk of cardiotoxicity, myopathy, rhabdomyolysis, GI or other bleeding (including life-threatening), other adverse effects (hepatic metabolism inhibited, additive effects, antiplatelet and anticoagulant effects augmented by vitamin E content in selumetinib capsules)

• sertraline
Nilceya (nilotinib)

+

sertraline

1 interaction

Avoid/Use Alternative

nilotinib + sertraline

use alternative or monitor ECG, electrolytes, bleeding s/sx: combo may incr. sertraline levels, risk of QT prolongation, cardiac arrhythmias, hyponatremia, GI or other bleeding (including life-threatening), other adverse effects (hepatic metabolism inhibited; additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake)

• sevoflurane
Nilceya (nilotinib)

+

sevoflurane

1 interaction

Avoid/Use Alternative

nilotinib + sevoflurane

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• simvastatin
Nilceya (nilotinib)

+

simvastatin

1 interaction

Avoid/Use Alternative

nilotinib + simvastatin

use alternative or monitor CK, myopathy sx; adjust max simvastatin dose to 10 mg/day: combo may incr. simvastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic metabolism inhibited)

• siponimod
Nilceya (nilotinib)

+

siponimod

1 interaction

Avoid/Use Alternative

nilotinib + siponimod

consider alternative or monitor HR, ECG, electrolytes; if also combined w/ strong CYP2C9 inhibitor, avoid combo: combo may incr. siponimod levels, risk of PR interval prolongation, AV block, bradycardia, QT prolongation, cardiac arrhythmias, serious infection, other adverse effects (hepatic metabolism inhibited, additive effects)

• smallpox vaccine, live
Nilceya (nilotinib)

+

smallpox vaccine, live

1 interaction

Avoid/Use Alternative

nilotinib + smallpox vaccine, live

avoid combo; vaccinate at least 4wk before or 3-6mo after nilotinib tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

• solifenacin
Nilceya (nilotinib)

+

solifenacin

1 interaction

Avoid/Use Alternative

nilotinib + solifenacin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• sonidegib
Nilceya (nilotinib)

+

sonidegib

1 interaction

Avoid/Use Alternative

nilotinib + sonidegib

avoid combo or monitor closely: combo may incr. sonidegib levels, risk of adverse effects (hepatic metabolism inhibited)

• sorafenib
Nilceya (nilotinib)

+

sorafenib

1 interaction

Avoid/Use Alternative

nilotinib + sorafenib

use alternative or monitor ECG, electrolytes, bleeding s/sx: combo may incr. risk of QT prolongation, cardiac arrhythmias, GI ulceration, perforation, bleeding, including life-threatening (additive effects)

• sotalol
Nilceya (nilotinib)

+

sotalol

1 interaction

Avoid/Use Alternative

nilotinib + sotalol

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• sotorasib
Nilceya (nilotinib)

+

sotorasib

1 interaction

Avoid/Use Alternative

nilotinib + sotorasib

consider alternative: combo may decr. nilotinib levels, efficacy (hepatic metabolism induced)

• St. John's wort
Nilceya (nilotinib)

+

St. John's wort

1 interaction

Avoid/Use Alternative

nilotinib + St. John's wort

avoid combo: combo may decr. nilotinib levels, efficacy (hepatic metabolism induced)

• sufentanil
Nilceya (nilotinib)

+

sufentanil

1 interaction

Avoid/Use Alternative

nilotinib + sufentanil

consider alternative or monitor respiratory rate, consider decr. sufentanil dose or frequency: combo may incr. sufentanil levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• tacrolimus
Nilceya (nilotinib)

+

tacrolimus

1 interaction

Avoid/Use Alternative

nilotinib + tacrolimus

consider alternative or monitor tacrolimus levels, ECG, electrolytes, renal fxn: combo may incr. tacrolimus levels, risk of QT prolongation, cardiac arrhythmias, nephrotoxicity, hyperkalemia, other adverse effects (hepatic metabolism inhibited, additive effects)

• taletrectinib
Nilceya (nilotinib)

+

taletrectinib

1 interaction

Avoid/Use Alternative

nilotinib + taletrectinib

avoid combo: combo may incr. taletrectinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• tazemetostat
Nilceya (nilotinib)

+

tazemetostat

1 interaction

Avoid/Use Alternative

nilotinib + tazemetostat

use alternative or monitor ECG, CBC; decr. tazemetostat dose as follows: if taking 800 mg bid, decr. tazemetostat dose to 400 mg bid; if taking 600 mg bid, decr. tazemetostat dose to 400 mg qam plus 200 mg qpm; if taking 400 mg bid, decr. tazemetostat dose to 200 mg bid: combo may incr. tazemetostat levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects; may decr. nilotinib levels, efficacy (hepatic metabolism inhibited, additive effects; hepatic metabolism induced)

• telavancin
Nilceya (nilotinib)

+

telavancin

1 interaction

Avoid/Use Alternative

nilotinib + telavancin

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• tetrabenazine
Nilceya (nilotinib)

+

tetrabenazine

1 interaction

Avoid/Use Alternative

nilotinib + tetrabenazine

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• tipranavir
Nilceya (nilotinib)

+

tipranavir

1 interaction

Avoid/Use Alternative

nilotinib + tipranavir

use alternative or monitor ECG, CBC, bleeding s/sx; decr. nilotinib dose as follows: newly diagnosed CML: if on nilotinib 300 mg bid, decr. to 200 mg qd; if on nilotinib 142 mg bid, decr. to 95 mg qd; resistant or intolerant CML: if on nilotinib 400 mg bid, decr. to 300 mg qd; if on nilotinib 190 mg bid, decr. to 142 mg qd: combo may incr. nilotinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, GI or other bleeding (including life-threatening), other adverse effects (hepatic metabolism inhibited, additive effects)

• tolvaptan
Nilceya (nilotinib)

+

tolvaptan

1 interaction

Avoid/Use Alternative

nilotinib + tolvaptan

HYPONATREMIA USE: avoid combo; AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DZ USE: monitor potassium; decr. tolvaptan total daily dose by 50% as follows: if taking 60 mg/day, decr. to 15 mg qam and 15 mg qpm; if taking 90 mg/day, decr. to 30 mg qam and 15 mg qpm; if taking 120 mg/day, decr. to 45 mg qam and 15 mg qpm: combo may incr. tolvaptan levels, risk of hyperkalemia, other adverse effects (hepatic metabolism inhibited, additive effects)

• toremifene
Nilceya (nilotinib)

+

toremifene

1 interaction

Avoid/Use Alternative

nilotinib + toremifene

avoid combo: combo may incr. toremifene levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• tramadol
Nilceya (nilotinib)

+

tramadol

1 interaction

Avoid/Use Alternative

nilotinib + tramadol

avoid combo: combo may incr. tramadol and active metabolite levels, risk of CNS and respiratory depression, psychomotor impairment, seizures, serotonin syndrome, QT prolongation, cardiac arrhythmias, severe hyponatremia, other adverse effects (hepatic metabolism inhibited, may incr. production of active metabolite; additive effects)

• trazodone
Nilceya (nilotinib)

+

trazodone

1 interaction

Avoid/Use Alternative

nilotinib + trazodone

use alternative or monitor ECG, electrolytes, BP, bleeding s/sx: combo may incr. trazodone levels, risk of QT prolongation, cardiac arrhythmias, hypotension (including orthostasis, syncope), GI or other bleeding (including life-threatening), hyponatremia, other adverse effects (hepatic metabolism inhibited, additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptakes)

• triclabendazole
Nilceya (nilotinib)

+

triclabendazole

1 interaction

Avoid/Use Alternative

nilotinib + triclabendazole

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• trifluridine
Nilceya (nilotinib)

+

trifluridine

1 interaction

Avoid/Use Alternative

nilotinib + trifluridine

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• triptorelin
Nilceya (nilotinib)

+

triptorelin

1 interaction

Avoid/Use Alternative

nilotinib + triptorelin

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• tucatinib
Nilceya (nilotinib)

+

tucatinib

1 interaction

Avoid/Use Alternative

nilotinib + tucatinib

use alternative or monitor ECG, CBC; decr. nilotinib dose as follows: newly diagnosed CML: if on nilotinib 300 mg bid, decr. to 200 mg qd; if on nilotinib 142 mg bid, decr. to 95 mg qd; resistant or intolerant CML: if on nilotinib 400 mg bid, decr. to 300 mg qd; if on nilotinib 190 mg bid, decr. to 142 mg qd: combo may incr. nilotinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited)

• typhoid vaccine, live
Nilceya (nilotinib)

+

typhoid vaccine, live

1 interaction

Avoid/Use Alternative

nilotinib + typhoid vaccine, live

avoid combo; vaccinate at least 4wk before or 3-6mo after nilotinib tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

• valganciclovir
Nilceya (nilotinib)

+

valganciclovir

1 interaction

Avoid/Use Alternative

nilotinib + valganciclovir

use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• valsartan
Nilceya (nilotinib)

+

valsartan

1 interaction

Avoid/Use Alternative

nilotinib + valsartan

consider alternative or monitor potassium: combo may incr. risk of hyperkalemia (additive effects)

• vandetanib
Nilceya (nilotinib)

+

vandetanib

1 interaction

Avoid/Use Alternative

nilotinib + vandetanib

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias, GI or other bleeding, including life-threatening (additive effects)

• vardenafil
Nilceya (nilotinib)

+

vardenafil

1 interaction

Avoid/Use Alternative

nilotinib + vardenafil

monitor ECG, electrolytes; max vardenafil dose 5 mg/24h; avoid combo w/ ODT form: combo may incr. vardenafil levels, risk of QT prolongation, cardiac arrhythmias, hypotension, priapism, other adverse effects (hepatic metabolism inhibited, additive effects)

• varicella vaccine, live
Nilceya (nilotinib)

+

varicella vaccine, live

1 interaction

Avoid/Use Alternative

nilotinib + varicella vaccine, live

avoid combo; vaccinate at least 4wk before or 3-6mo after nilotinib tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

• vemurafenib
Nilceya (nilotinib)

+

vemurafenib

1 interaction

Avoid/Use Alternative

nilotinib + vemurafenib

avoid combo: combo may incr. vemurafenib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects; may decr. nilotinib levels, efficacy (hepatic metabolism inhibited, additive effects; hepatic metabolism induced)

• venetoclax
Nilceya (nilotinib)

+

venetoclax

1 interaction

Avoid/Use Alternative

nilotinib + venetoclax

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited)

• vonoprazan
Nilceya (nilotinib)

+

vonoprazan

1 interaction

Avoid/Use Alternative

nilotinib + vonoprazan

use alternative, incl. H2 blockers 10h before or 2h after nilotinib or short-acting antacids 2h before or 2h after nilotinib: combo may decr. nilotinib levels, efficacy (absorption decreased at higher gastric pH)

• voriconazole
Nilceya (nilotinib)

+

voriconazole

1 interaction

Avoid/Use Alternative

nilotinib + voriconazole

use alternative or monitor ECG, electrolytes, CBC; decr. nilotinib dose as follows: newly diagnosed CML: if on nilotinib 300 mg bid, decr. to 200 mg qd; if on nilotinib 142 mg bid, decr. to 95 mg qd; resistant or intolerant CML: if on nilotinib 400 mg bid, decr. to 300 mg qd; if on nilotinib 190 mg bid, decr. to 142 mg qd: combo may incr. nilotinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

• yellow fever vaccine, live
Nilceya (nilotinib)

+

yellow fever vaccine, live

1 interaction

Avoid/Use Alternative

nilotinib + yellow fever vaccine, live

avoid combo; vaccinate at least 4wk before or 3-6mo after nilotinib tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

• ziftomenib
Nilceya (nilotinib)

+

ziftomenib

1 interaction

Avoid/Use Alternative

nilotinib + ziftomenib

avoid combo: combo may incr. ziftomenib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

Monitor/Modify Tx

• abemaciclib
Nilceya (nilotinib)

+

abemaciclib

1 interaction

Monitor/Modify Tx

nilotinib + abemaciclib

consider decr. abemaciclib 200 mg bid dose to 150 mg bid, abemaciclib 150 mg bid dose to 100 mg bid, abemaciclib 100 mg bid dose to 50 mg bid; monitor CBC: combo may incr. abemaciclib levels, risk of serious infection, myelosuppression, thrombosis risk, other adverse effects (hepatic metabolism inhibited)

• abiraterone acetate
Nilceya (nilotinib)

+

abiraterone acetate

1 interaction

Monitor/Modify Tx

nilotinib + abiraterone acetate

monitor potassium: combo may incr. risk of hypokalemia (additive effects)

• acalabrutinib
Nilceya (nilotinib)

+

acalabrutinib

1 interaction

Monitor/Modify Tx

nilotinib + acalabrutinib

decr. acalabrutinib dose to 100 mg qd; monitor CBC, bleeding s/sx: combo may incr. acalabrutinib levels, risk of serious infection, myelosuppression, GI or other bleeding (including life-threatening), other adverse effects (hepatic metabolism inhibited, additive effects)

• acetazolamide
Nilceya (nilotinib)

+

acetazolamide

1 interaction

Monitor/Modify Tx

nilotinib + acetazolamide

monitor potassium, sodium: combo may incr. risk of hypokalemia, hyponatremia (additive effects)

• ado-trastuzumab emtansine
Nilceya (nilotinib)

+

ado-trastuzumab emtansine

1 interaction

Monitor/Modify Tx

nilotinib + ado-trastuzumab emtansine

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

• afatinib
Nilceya (nilotinib)

+

afatinib

1 interaction

Monitor/Modify Tx

nilotinib + afatinib

monitor bleeding s/sx: combo may incr. risk of GI ulceration, perforation, bleeding, including life-threatening (additive effects)

• albendazole
Nilceya (nilotinib)

+

albendazole

1 interaction

Monitor/Modify Tx

nilotinib + albendazole

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• albuterol
Nilceya (nilotinib)

+

albuterol

1 interaction

Monitor/Modify Tx

nilotinib + albuterol

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias, hypokalemia (additive effects)

• albuterol inhaled
Nilceya (nilotinib)

+

albuterol inhaled

1 interaction

Monitor/Modify Tx

nilotinib + albuterol inhaled

monitor ECG, electrolytes: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

• alemtuzumab
Nilceya (nilotinib)

+

alemtuzumab

1 interaction

Monitor/Modify Tx

nilotinib + alemtuzumab

monitor CBC; myelosuppression risk may be lower w/ alemtuzumab doses used for MS: combo may incr. risk of myelosuppression (additive effects)

• alendronate
Nilceya (nilotinib)

+

alendronate

1 interaction

Monitor/Modify Tx

nilotinib + alendronate

monitor calcium, bleeding s/sx: combo may incr. risk of hypocalcemia, upper GI ulceration, perforation, bleeding, including life-threatening (additive effects)

• alfuzosin
Nilceya (nilotinib)

+

alfuzosin

1 interaction

Monitor/Modify Tx

nilotinib + alfuzosin

monitor BP, ECG, electrolytes: combo may incr. alfuzosin levels, risk of QT prolongation, cardiac arrhythmias, hypotension (including orthostasis, syncope), other adverse effects (hepatic metabolism inhibited, additive effects)

• aliskiren
Nilceya (nilotinib)

+

aliskiren

1 interaction

Monitor/Modify Tx

nilotinib + aliskiren

monitor potassium: combo may incr. aliskiren levels, risk of hyperkalemia, other adverse effects (hepatic metabolism inhibited, additive effects)

• allopurinol
Nilceya (nilotinib)

+

allopurinol

1 interaction

Monitor/Modify Tx

nilotinib + allopurinol

monitor CBC, uric acid levels: combo may incr. risk of myelosuppression; may decr. allopurinol efficacy (additive effects; antagonistic effects)

• aloe
Nilceya (nilotinib)

+

aloe

1 interaction

Monitor/Modify Tx

nilotinib + aloe

monitor potassium w/ aloe laxative doses: combo may incr. risk of hypokalemia (additive effects)

• alpha-tocopherol (vitamin E)
Nilceya (nilotinib)

+

alpha-tocopherol (vitamin E)

1 interaction

Monitor/Modify Tx

nilotinib + alpha-tocopherol (vitamin E)

monitor bleeding signs/symptoms, especially with alpha-tocopherol doses >800 units/day: combo may increase risk of GI or other bleeding, including life-threatening (additive effects)

• alprostadil intracavernous
Nilceya (nilotinib)

+

alprostadil intracavernous

1 interaction

Monitor/Modify Tx

nilotinib + alprostadil intracavernous

monitor injection site bleeding signs/symptoms: combo may increase risk of localized bleeding (additive effects)

• alprostadil intravenous
Nilceya (nilotinib)

+

alprostadil intravenous

1 interaction

Monitor/Modify Tx

nilotinib + alprostadil intravenous

monitor bleeding signs/symptoms: combo may increase risk of GI or other bleeding, including life-threatening (additive effects)

• alteplase
Nilceya (nilotinib)

+

alteplase

1 interaction

Monitor/Modify Tx

nilotinib + alteplase

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

• aluminum hydroxide
Nilceya (nilotinib)

+

aluminum hydroxide

1 interaction

Monitor/Modify Tx

nilotinib + aluminum hydroxide

separate admin. by at least 2h: combo may decr. nilotinib levels, efficacy (absorption decreased at higher gastric pH)

• amifostine
Nilceya (nilotinib)

+

amifostine

1 interaction

Monitor/Modify Tx

nilotinib + amifostine

monitor calcium: combo may incr. risk of hypocalcemia (additive effects)

• amisulpride
Nilceya (nilotinib)

+

amisulpride

1 interaction

Monitor/Modify Tx

nilotinib + amisulpride

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• amitriptyline
Nilceya (nilotinib)

+

amitriptyline

1 interaction

Monitor/Modify Tx

nilotinib + amitriptyline

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• amphotericin
Nilceya (nilotinib)

+

amphotericin

1 interaction

Monitor/Modify Tx

nilotinib + amphotericin

monitor potassium, ECG: combo may incr. risk of hypokalemia, cardiac arrhythmias (additive effects)

• anacaulase topical
Nilceya (nilotinib)

+

anacaulase topical

1 interaction

Monitor/Modify Tx

nilotinib + anacaulase topical

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

• anthrax vaccine
Nilceya (nilotinib)

+

anthrax vaccine

1 interaction

Monitor/Modify Tx

nilotinib + anthrax vaccine

if possible, vaccinate at least 2wk before starting nilotinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• anti-thymocyte globulin
Nilceya (nilotinib)

+

anti-thymocyte globulin

1 interaction

Monitor/Modify Tx

nilotinib + anti-thymocyte globulin

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• antithrombin
Nilceya (nilotinib)

+

antithrombin

1 interaction

Monitor/Modify Tx

nilotinib + antithrombin

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

• apixaban
Nilceya (nilotinib)

+

apixaban

1 interaction

Monitor/Modify Tx

nilotinib + apixaban

monitor bleeding s/sx, especially if also combined w/ P-gp inhibitor: combo may incr. apixaban levels, risk of GI or other bleeding (including life-threatening), other adverse effects (hepatic metabolism inhibited, additive effects)

• arformoterol inhaled
Nilceya (nilotinib)

+

arformoterol inhaled

1 interaction

Monitor/Modify Tx

nilotinib + arformoterol inhaled

monitor ECG, electrolytes: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

• argatroban
Nilceya (nilotinib)

+

argatroban

1 interaction

Monitor/Modify Tx

nilotinib + argatroban

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

• aripiprazole oral
Nilceya (nilotinib)

+

aripiprazole oral

1 interaction

Monitor/Modify Tx

nilotinib + aripiprazole oral

consider decr. PO aripiprazole dose; if also CYP2D6 PM or if also combined w/ strong CYP2D6 inhibitor, consider decr. PO aripiprazole dose up to 75%; no dose adjustment if depression adjunct tx use: combo may incr. aripiprazole levels, risk of adverse effects (hepatic metabolism inhibited)

• asciminib
Nilceya (nilotinib)

+

asciminib

1 interaction

Monitor/Modify Tx

nilotinib + asciminib

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• asparaginase
Nilceya (nilotinib)

+

asparaginase

1 interaction

Monitor/Modify Tx

nilotinib + asparaginase

monitor potassium, bleeding s/sx: combo may incr. risk of hypokalemia, GI or other bleeding, including life-threatening (additive effects)

• aspirin
Nilceya (nilotinib)

+

aspirin

1 interaction

Monitor/Modify Tx

nilotinib + aspirin

monitor bleeding s/sx: combo may incr. risk of GI ulceration, perforation, bleeding, including life-threatening (additive effects)

• atidarsagene autotemcel
Nilceya (nilotinib)

+

atidarsagene autotemcel

1 interaction

Monitor/Modify Tx

nilotinib + atidarsagene autotemcel

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression (additive effects)

• atorvastatin
Nilceya (nilotinib)

+

atorvastatin

1 interaction

Monitor/Modify Tx

nilotinib + atorvastatin

monitor CK, myopathy sx: combo may incr. atorvastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic metabolism inhibited)

• auranofin
Nilceya (nilotinib)

+

auranofin

1 interaction

Monitor/Modify Tx

nilotinib + auranofin

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• avacopan
Nilceya (nilotinib)

+

avacopan

1 interaction

Monitor/Modify Tx

nilotinib + avacopan

monitor ECG, CBC: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited)

• avanafil
Nilceya (nilotinib)

+

avanafil

1 interaction

Monitor/Modify Tx

nilotinib + avanafil

monitor BP; adjust max avanafil dose to 50 mg/24h: combo may incr. avanafil levels, risk of hypotension, priapism, other adverse effects (hepatic metabolism inhibited)

• avatrombopag
Nilceya (nilotinib)

+

avatrombopag

1 interaction

Monitor/Modify Tx

nilotinib + avatrombopag

CHRONIC IMMUNE THROMBOCYTOPENIA: monitor platelets, thrombosis s/sx; if avatrombopag tablet also combined w/ a moderate or strong CYP2C9 inhibitor, decr. start dose to 20 mg 3x/wk; if avatrombopag sprinkle also combined w/ a moderate or strong CYP2C9 inhibitor, decr. start dose to 10 mg 3x/wk; CHRONIC LIVER DZ: monitor platelets, thrombosis s/sx: combo may incr. avatrombopag levels, risk of thromboembolism, other adverse effects (hepatic metabolism inhibited)

• axitinib
Nilceya (nilotinib)

+

axitinib

1 interaction

Monitor/Modify Tx

nilotinib + axitinib

monitor bleeding s/sx; consider decr. axitinib dose: combo may incr. axitinib levels, risk of GI ulceration, perforation, bleeding (including life-threatening), other adverse effects (hepatic metabolism inhibited, additive effects)

• azathioprine
Nilceya (nilotinib)

+

azathioprine

1 interaction

Monitor/Modify Tx

nilotinib + azathioprine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• balsalazide
Nilceya (nilotinib)

+

balsalazide

1 interaction

Monitor/Modify Tx

nilotinib + balsalazide

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• baricitinib
Nilceya (nilotinib)

+

baricitinib

1 interaction

Monitor/Modify Tx

nilotinib + baricitinib

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• benazepril
Nilceya (nilotinib)

+

benazepril

1 interaction

Monitor/Modify Tx

nilotinib + benazepril

monitor potassium: combo may incr. risk of hyperkalemia (additive effects)

• benznidazole
Nilceya (nilotinib)

+

benznidazole

1 interaction

Monitor/Modify Tx

nilotinib + benznidazole

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• berotralstat
Nilceya (nilotinib)

+

berotralstat

1 interaction

Monitor/Modify Tx

nilotinib + berotralstat

monitor ECG, electrolytes, CBC: combo may incr. nilotinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

• betamethasone
Nilceya (nilotinib)

+

betamethasone

1 interaction

Monitor/Modify Tx

nilotinib + betamethasone

monitor potassium, bleeding s/sx: combo may incr. risk of hypokalemia, GI ulceration, perforation, bleeding, including life-threatening (additive effects)

• betibeglogene autotemcel
Nilceya (nilotinib)

+

betibeglogene autotemcel

1 interaction

Monitor/Modify Tx

nilotinib + betibeglogene autotemcel

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression (additive effects)

• bevacizumab
Nilceya (nilotinib)

+

bevacizumab

1 interaction

Monitor/Modify Tx

nilotinib + bevacizumab

monitor bleeding s/sx: combo may incr. risk of GI ulceration, perforation, bleeding, including life-threatening (additive effects)

• binimetinib
Nilceya (nilotinib)

+

binimetinib

1 interaction

Monitor/Modify Tx

nilotinib + binimetinib

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

• bivalirudin
Nilceya (nilotinib)

+

bivalirudin

1 interaction

Monitor/Modify Tx

nilotinib + bivalirudin

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

• brentuximab vedotin
Nilceya (nilotinib)

+

brentuximab vedotin

1 interaction

Monitor/Modify Tx

nilotinib + brentuximab vedotin

monitor bleeding s/sx: combo may incr. risk of GI ulceration, perforation, bleeding, including life-threatening (additive effects)

• brexpiprazole
Nilceya (nilotinib)

+

brexpiprazole

1 interaction

Monitor/Modify Tx

nilotinib + brexpiprazole

if CYP2D6 poor metabolizer or if also combined w/ moderate or strong CYP2D6 inhibitor, decr. brexpiprazole dose 75%: combo may incr. brexpiprazole levels, risk of adverse effects (hepatic metabolism inhibited)

• bromelain
Nilceya (nilotinib)

+

bromelain

1 interaction

Monitor/Modify Tx

nilotinib + bromelain

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

• bromfenac ophthalmic
Nilceya (nilotinib)

+

bromfenac ophthalmic

1 interaction

Monitor/Modify Tx

nilotinib + bromfenac ophthalmic

monitor bleeding s/sx: combo may incr. risk of postop ocular bleeding (additive effects)

• bromocriptine
Nilceya (nilotinib)

+

bromocriptine

1 interaction

Monitor/Modify Tx

nilotinib + bromocriptine

limit bromocriptine max dose to 1.6 mg/day if diabetes tx; otherwise, caution advised: combo may incr. bromocriptine levels, risk of hypotension, other adverse effects (hepatic metabolism inhibited)

• budesonide
Nilceya (nilotinib)

+

budesonide

1 interaction

Monitor/Modify Tx

nilotinib + budesonide

monitor potassium, hypercorticism s/sx: combo may incr. budesonide levels, risk of systemic corticosteroid effects, including Cushing syndrome, adrenal suppression, serious infection, hypokalemia, other adverse effects (hepatic metabolism inhibited, additive effects)

• bumetanide
Nilceya (nilotinib)

+

bumetanide

1 interaction

Monitor/Modify Tx

nilotinib + bumetanide

monitor potassium, calcium, sodium: combo may incr. risk of hypokalemia, hypocalcemia, hyponatremia (additive effects)

• buprenorphine
Nilceya (nilotinib)

+

buprenorphine

1 interaction

Monitor/Modify Tx

nilotinib + buprenorphine

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• butorphanol
Nilceya (nilotinib)

+

butorphanol

1 interaction

Monitor/Modify Tx

nilotinib + butorphanol

monitor respiratory rate, consider decr. butorphanol dose: combo may incr. butorphanol levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• cabazitaxel
Nilceya (nilotinib)

+

cabazitaxel

1 interaction

Monitor/Modify Tx

nilotinib + cabazitaxel

monitor bleeding s/sx: combo may incr. risk of GI ulceration, perforation, bleeding, including life-threatening (additive effects)

• calaspargase
Nilceya (nilotinib)

+

calaspargase

1 interaction

Monitor/Modify Tx

nilotinib + calaspargase

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

• calcitonin-salmon
Nilceya (nilotinib)

+

calcitonin-salmon

1 interaction

Monitor/Modify Tx

nilotinib + calcitonin-salmon

monitor calcium: combo may incr. risk of hypocalcemia, tetany, seizures (additive effects)

• calcium carbonate
Nilceya (nilotinib)

+

calcium carbonate

1 interaction

Monitor/Modify Tx

nilotinib + calcium carbonate

separate admin. by at least 2h: combo may decr. nilotinib levels, efficacy (absorption decreased at higher gastric pH)

• candesartan cilexetil
Nilceya (nilotinib)

+

candesartan cilexetil

1 interaction

Monitor/Modify Tx

nilotinib + candesartan cilexetil

monitor potassium: combo may incr. risk of hyperkalemia (additive effects)

• cangrelor
Nilceya (nilotinib)

+

cangrelor

1 interaction

Monitor/Modify Tx

nilotinib + cangrelor

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

• capivasertib
Nilceya (nilotinib)

+

capivasertib

1 interaction

Monitor/Modify Tx

nilotinib + capivasertib

monitor glucose; decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• caplacizumab
Nilceya (nilotinib)

+

caplacizumab

1 interaction

Monitor/Modify Tx

nilotinib + caplacizumab

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

• captopril
Nilceya (nilotinib)

+

captopril

1 interaction

Monitor/Modify Tx

nilotinib + captopril

monitor potassium: combo may incr. risk of hyperkalemia (additive effects)

• carfilzomib
Nilceya (nilotinib)

+

carfilzomib

1 interaction

Monitor/Modify Tx

nilotinib + carfilzomib

monitor potassium, bleeding s/sx: combo may incr. risk of hypokalemia, GI or other bleeding, including life-threatening (additive effects)

• celecoxib
Nilceya (nilotinib)

+

celecoxib

1 interaction

Monitor/Modify Tx

nilotinib + celecoxib

monitor potassium, bleeding s/sx: combo may incr. risk of hyperkalemia, GI ulceration, perforation, bleeding, including life-threatening (additive effects)

• cetuximab
Nilceya (nilotinib)

+

cetuximab

1 interaction

Monitor/Modify Tx

nilotinib + cetuximab

monitor potassium, calcium: combo may incr. risk of hypokalemia, hypocalcemia (additive effects)

• chikungunya vaccine
Nilceya (nilotinib)

+

chikungunya vaccine

1 interaction

Monitor/Modify Tx

nilotinib + chikungunya vaccine

if possible, vaccinate at least 2wk before starting nilotinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• chlorothiazide
Nilceya (nilotinib)

+

chlorothiazide

1 interaction

Monitor/Modify Tx

nilotinib + chlorothiazide

monitor potassium, sodium: combo may incr. risk of hypokalemia, hyponatremia, seizures (additive effects)

• chlorpromazine
Nilceya (nilotinib)

+

chlorpromazine

1 interaction

Monitor/Modify Tx

nilotinib + chlorpromazine

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• chlorthalidone
Nilceya (nilotinib)

+

chlorthalidone

1 interaction

Monitor/Modify Tx

nilotinib + chlorthalidone

monitor potassium, sodium: combo may incr. risk of hypokalemia, hyponatremia (additive effects)

• cidofovir
Nilceya (nilotinib)

+

cidofovir

1 interaction

Monitor/Modify Tx

nilotinib + cidofovir

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• cilostazol
Nilceya (nilotinib)

+

cilostazol

1 interaction

Monitor/Modify Tx

nilotinib + cilostazol

monitor bleeding s/sx; decr. cilostazol dose to 50 mg bid: combo may incr. cilostazol levels, risk of GI or other bleeding (including life-threatening), other adverse effects (hepatic metabolism inhibited, additive effects)

• cimetidine
Nilceya (nilotinib)

+

cimetidine

1 interaction

Monitor/Modify Tx

nilotinib + cimetidine

give nilotinib 2h before or 10h after cimetidine: combo may decr. nilotinib levels, efficacy (absorption decreased at higher gastric pH)

• cinacalcet
Nilceya (nilotinib)

+

cinacalcet

1 interaction

Monitor/Modify Tx

nilotinib + cinacalcet

monitor calcium, ECG, bleeding s/sx: combo may incr. risk of severe hypocalcemia (including life-threatening), QT prolongation, cardiac arrhythmias, seizures, GI ulceration, perforation, bleeding, including life-threatening (additive effects)

• ciprofloxacin
Nilceya (nilotinib)

+

ciprofloxacin

1 interaction

Monitor/Modify Tx

nilotinib + ciprofloxacin

monitor ECG, electrolytes, CBC: combo may incr. nilotinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

• cisplatin
Nilceya (nilotinib)

+

cisplatin

1 interaction

Monitor/Modify Tx

nilotinib + cisplatin

monitor potassium, calcium, sodium: combo may incr. risk of hypokalemia, hypocalcemia, tetany, hyponatremia (additive effects)

• clomipramine
Nilceya (nilotinib)

+

clomipramine

1 interaction

Monitor/Modify Tx

nilotinib + clomipramine

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias, hyponatremia (additive effects)

• clonazepam
Nilceya (nilotinib)

+

clonazepam

1 interaction

Monitor/Modify Tx

nilotinib + clonazepam

monitor respiratory rate: combo may incr. clonazepam levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• clopidogrel
Nilceya (nilotinib)

+

clopidogrel

1 interaction

Monitor/Modify Tx

nilotinib + clopidogrel

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

• clozapine
Nilceya (nilotinib)

+

clozapine

1 interaction

Monitor/Modify Tx

nilotinib + clozapine

monitor CBC, ECG, BP, HR, electrolytes; consider decr. clozapine dose: combo may incr. clozapine levels, risk of QT prolongation, cardiac arrhythmias, hypotension, bradycardia, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

• collagenase clostridium histolyticum
Nilceya (nilotinib)

+

collagenase clostridium histolyticum

1 interaction

Monitor/Modify Tx

nilotinib + collagenase clostridium histolyticum

monitor injection site bleeding s/sx: combo may incr. risk of localized bleeding, including severe (additive effects)

• copanlisib
Nilceya (nilotinib)

+

copanlisib

1 interaction

Monitor/Modify Tx

nilotinib + copanlisib

monitor CBC: combo may incr. copanlisib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited)

• copper histidinate
Nilceya (nilotinib)

+

copper histidinate

1 interaction

Monitor/Modify Tx

nilotinib + copper histidinate

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• corticotropin
Nilceya (nilotinib)

+

corticotropin

1 interaction

Monitor/Modify Tx

nilotinib + corticotropin

monitor potassium, bleeding s/sx: combo may incr. risk of hypokalemia, GI ulceration, perforation, bleeding, including life-threatening (additive effects)

• cortisone
Nilceya (nilotinib)

+

cortisone

1 interaction

Monitor/Modify Tx

nilotinib + cortisone

monitor potassium, bleeding s/sx: combo may incr. risk of hypokalemia, GI ulceration, perforation, bleeding, including life-threatening (additive effects)

• COVID-19 vaccine
Nilceya (nilotinib)

+

COVID-19 vaccine

1 interaction

Monitor/Modify Tx

nilotinib + COVID-19 vaccine

if possible, vaccinate at least 2wk before or 3mo after nilotinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• cyclophosphamide
Nilceya (nilotinib)

+

cyclophosphamide

1 interaction

Monitor/Modify Tx

nilotinib + cyclophosphamide

monitor CBC, sodium: combo may decr. cyclophosphamide active metabolite levels, efficacy; may incr. risk of myelosuppression, hyponatremia, including life-threatening (hepatic metabolism possibly inhibited, decr. conversion to active metabolite; additive effects)

• cyclosporine
Nilceya (nilotinib)

+

cyclosporine

1 interaction

Monitor/Modify Tx

nilotinib + cyclosporine

monitor cyclosporine levels, renal fxn, ECG, CBC, potassium: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, hyperkalemia, serious infection, nephrotoxicity, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

• cysteamine
Nilceya (nilotinib)

+

cysteamine

1 interaction

Monitor/Modify Tx

nilotinib + cysteamine

monitor bleeding s/sx: combo may incr. risk of GI ulceration, perforation, bleeding, including life-threatening (additive effects)

• dabigatran
Nilceya (nilotinib)

+

dabigatran

1 interaction

Monitor/Modify Tx

nilotinib + dabigatran

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

• dalteparin
Nilceya (nilotinib)

+

dalteparin

1 interaction

Monitor/Modify Tx

nilotinib + dalteparin

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

• danazol
Nilceya (nilotinib)

+

danazol

1 interaction

Monitor/Modify Tx

nilotinib + danazol

monitor ECG, CBC: combo may incr. nilotinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited)

• danshen
Nilceya (nilotinib)

+

danshen

1 interaction

Monitor/Modify Tx

nilotinib + danshen

monitor bleeding s/sx: combo may decr. nilotinib levels, efficacy; may incr. risk of GI or other bleeding, including life-threatening (hepatic metabolism induced; additive effects)

• dapsone
Nilceya (nilotinib)

+

dapsone

1 interaction

Monitor/Modify Tx

nilotinib + dapsone

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• daridorexant
Nilceya (nilotinib)

+

daridorexant

1 interaction

Monitor/Modify Tx

nilotinib + daridorexant

adjust max daridorexant dose to 25 mg/day: combo may incr. daridorexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• darunavir
Nilceya (nilotinib)

+

darunavir

1 interaction

Monitor/Modify Tx

nilotinib + darunavir

monitor ECG, CBC: combo may incr. nilotinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited)

• dasatinib
Nilceya (nilotinib)

+

dasatinib

1 interaction

Monitor/Modify Tx

nilotinib + dasatinib

monitor ECG, electrolytes, CBC, bleeding s/sx: combo may incr. dasatinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, GI or other bleeding (including life-threatening), other adverse effects (hepatic metabolism inhibited, additive effects)

• decitabine
Nilceya (nilotinib)

+

decitabine

1 interaction

Monitor/Modify Tx

nilotinib + decitabine

monitor potassium w/ IV decitabine use: combo may alter serum potassium levels (additive effects)

• deferasirox
Nilceya (nilotinib)

+

deferasirox

1 interaction

Monitor/Modify Tx

nilotinib + deferasirox

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, GI ulceration, perforation, bleeding, including life-threatening (additive effects)

• defibrotide
Nilceya (nilotinib)

+

defibrotide

1 interaction

Monitor/Modify Tx

nilotinib + defibrotide

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

• deflazacort
Nilceya (nilotinib)

+

deflazacort

1 interaction

Monitor/Modify Tx

nilotinib + deflazacort

decr. deflazacort to 1/3 usual dose; monitor potassium, bleeding s/sx: combo may incr. deflazacort active metabolite levels, risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, GI ulceration, perforation, bleeding (including life-threatening), hypokalemia, other adverse effects (hepatic metabolism inhibited, additive effects)

• denosumab
Nilceya (nilotinib)

+

denosumab

1 interaction

Monitor/Modify Tx

nilotinib + denosumab

monitor calcium: combo may incr. risk of severe hypocalcemia, including life-threatening (additive effects)

• desmopressin
Nilceya (nilotinib)

+

desmopressin

1 interaction

Monitor/Modify Tx

nilotinib + desmopressin

monitor sodium: combo may incr. risk of hyponatremia, including life-threatening (additive effects)

• desvenlafaxine
Nilceya (nilotinib)

+

desvenlafaxine

1 interaction

Monitor/Modify Tx

nilotinib + desvenlafaxine

monitor sodium, bleeding s/sx: combo may incr. risk of hyponatremia, GI or other bleeding, including life-threatening (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake)

• deuruxolitinib
Nilceya (nilotinib)

+

deuruxolitinib

1 interaction

Monitor/Modify Tx

nilotinib + deuruxolitinib

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, serious infection, GI ulceration, perforation, bleeding, including life-threatening (additive effects)

• deutetrabenazine
Nilceya (nilotinib)

+

deutetrabenazine

1 interaction

Monitor/Modify Tx

nilotinib + deutetrabenazine

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• dexamethasone
Nilceya (nilotinib)

+

dexamethasone

1 interaction

Monitor/Modify Tx

nilotinib + dexamethasone

monitor potassium, bleeding s/sx: combo may incr. dexamethasone levels, risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, serious infection, hypokalemia, GI ulceration, perforation, bleeding (including life-threatening), other adverse effects; may decr. nilotinib levels, efficacy (hepatic metabolism inhibited, additive effects; hepatic metabolism induced)

• dichlorphenamide
Nilceya (nilotinib)

+

dichlorphenamide

1 interaction

Monitor/Modify Tx

nilotinib + dichlorphenamide

monitor potassium: combo may incr. risk of hypokalemia (additive effects)

• diclofenac
Nilceya (nilotinib)

+

diclofenac

1 interaction

Monitor/Modify Tx

nilotinib + diclofenac

monitor potassium, bleeding s/sx: combo may incr. risk of hyperkalemia, GI ulceration, perforation, bleeding, including life-threatening (additive effects)

• diclofenac ophthalmic
Nilceya (nilotinib)

+

diclofenac ophthalmic

1 interaction

Monitor/Modify Tx

nilotinib + diclofenac ophthalmic

monitor bleeding s/sx: combo may incr. risk of postop ocular bleeding (additive effects)

• diclofenac topical
Nilceya (nilotinib)

+

diclofenac topical

1 interaction

Monitor/Modify Tx

nilotinib + diclofenac topical

monitor potassium, bleeding s/sx: combo may incr. risk of hyperkalemia, GI ulceration, perforation, bleeding, including life-threatening (additive effects)

• diflunisal
Nilceya (nilotinib)

+

diflunisal

1 interaction

Monitor/Modify Tx

nilotinib + diflunisal

monitor potassium, bleeding s/sx: combo may incr. risk of hyperkalemia, GI ulceration, perforation, bleeding, including life-threatening (additive effects)

• digoxin
Nilceya (nilotinib)

+

digoxin

1 interaction

Monitor/Modify Tx

nilotinib + digoxin

monitor electrolytes: combo may incr. risk of digoxin toxicity, cardiac arrhythmias (electrolyte abnormalities may incr. digoxin sensitivity)

• diltiazem
Nilceya (nilotinib)

+

diltiazem

1 interaction

Monitor/Modify Tx

nilotinib + diltiazem

monitor ECG, CBC: combo may incr. nilotinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited)

• dimethyl fumarate
Nilceya (nilotinib)

+

dimethyl fumarate

1 interaction

Monitor/Modify Tx

nilotinib + dimethyl fumarate

monitor bleeding s/sx: combo may incr. risk of GI ulceration, perforation, bleeding, including life-threatening (additive effects)

• dinutuximab
Nilceya (nilotinib)

+

dinutuximab

1 interaction

Monitor/Modify Tx

nilotinib + dinutuximab

monitor potassium, sodium, calcium: combo may incr. risk of hypokalemia, severe hyponatremia, hypocalcemia (additive effects)

• diosmin
Nilceya (nilotinib)

+

diosmin

1 interaction

Monitor/Modify Tx

nilotinib + diosmin

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

• diphtheria/tetanus vaccine
Nilceya (nilotinib)

+

diphtheria/ tetanus vaccine

1 interaction

Monitor/Modify Tx

nilotinib + diphtheria/ tetanus vaccine

if possible, vaccinate at least 2wk before starting nilotinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• diphtheria/tetanus/pertussis vaccine
Nilceya (nilotinib)

+

diphtheria/ tetanus/ pertussis vaccine

1 interaction

Monitor/Modify Tx

nilotinib + diphtheria/ tetanus/ pertussis vaccine

if possible, vaccinate at least 2wk before starting nilotinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• dipyridamole
Nilceya (nilotinib)

+

dipyridamole

1 interaction

Monitor/Modify Tx

nilotinib + dipyridamole

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

• diroximel fumarate
Nilceya (nilotinib)

+

diroximel fumarate

1 interaction

Monitor/Modify Tx

nilotinib + diroximel fumarate

monitor bleeding s/sx: combo may incr. risk of GI ulceration, perforation, bleeding, including life-threatening (additive effects)

• docetaxel
Nilceya (nilotinib)

+

docetaxel

1 interaction

Monitor/Modify Tx

nilotinib + docetaxel

monitor CBC; consider decr. docetaxel dose: combo may incr. docetaxel levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited)

• drospirenone (contraceptive)
Nilceya (nilotinib)

+

drospirenone (contraceptive)

1 interaction

Monitor/Modify Tx

nilotinib + drospirenone (contraceptive)

monitor potassium: combo may incr. risk of hyperkalemia (additive effects)

• drospirenone (hormone replacement)
Nilceya (nilotinib)

+

drospirenone (hormone replacement)

1 interaction

Monitor/Modify Tx

nilotinib + drospirenone (hormone replacement)

monitor potassium: combo may incr. risk of hyperkalemia (additive effects)

• duloxetine
Nilceya (nilotinib)

+

duloxetine

1 interaction

Monitor/Modify Tx

nilotinib + duloxetine

monitor bleeding s/sx, sodium: combo may incr. risk of hyponatremia, GI or other bleeding, including life-threatening (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake)

• duvelisib
Nilceya (nilotinib)

+

duvelisib

1 interaction

Monitor/Modify Tx

nilotinib + duvelisib

monitor ECG, CBC: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited)

• ebola vaccine, live
Nilceya (nilotinib)

+

ebola vaccine, live

1 interaction

Monitor/Modify Tx

nilotinib + ebola vaccine, live

consider vaccinating at least 4wk before or 3mo after nilotinib tx: combo may result in inadequate vaccine response; may incr. risk of mild vesicular stomatitis virus infection (immunosuppressive effects, recombinant vaccine with vesicular stomatitis virus vector)

• edoxaban
Nilceya (nilotinib)

+

edoxaban

1 interaction

Monitor/Modify Tx

nilotinib + edoxaban

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

• efbemalenograstim alfa
Nilceya (nilotinib)

+

efbemalenograstim alfa

1 interaction

Monitor/Modify Tx

nilotinib + efbemalenograstim alfa

admin. efbemalenograstim at least 24h after or at least 14 days before myelosuppressive chemo: combo may decr. efbemalenograstim efficacy (antagonistic effects)

• eflapegrastim (G-CSF)
Nilceya (nilotinib)

+

eflapegrastim (G-CSF)

1 interaction

Monitor/Modify Tx

nilotinib + eflapegrastim (G-CSF)

admin. eflapegrastim >24h after or >14 days before myelosuppressive chemo: combo may decr. eflapegrastim efficacy (antagonistic effects)

• elexacaftor/tezacaftor/ivacaftor
Nilceya (nilotinib)

+

elexacaftor/ tezacaftor/ ivacaftor

1 interaction

Monitor/Modify Tx

nilotinib + elexacaftor/ tezacaftor/ ivacaftor

2-5 YO: decr. usual morning dose by alternating between one elexacaftor/tezacaftor/ivacaftor packet (Day 1) and one ivacaftor packet (Day 2), no evening doses; 6 YO AND OLDER: decr. usual morning dose by alternating between two elexacaftor/tezacaftor/ivacaftor tablets (Day 1) and one ivacaftor tablet (Day 2), no evening doses: combo may incr. elexacaftor/tezacaftor/ivacaftor levels, risk of adverse effects (hepatic metabolism inhibited)

• elinzanetant
Nilceya (nilotinib)

+

elinzanetant

1 interaction

Monitor/Modify Tx

nilotinib + elinzanetant

decr. elinzanetant dose to 60 mg daily: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• elivaldogene autotemcel
Nilceya (nilotinib)

+

elivaldogene autotemcel

1 interaction

Monitor/Modify Tx

nilotinib + elivaldogene autotemcel

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression (additive effects)

• emapalumab
Nilceya (nilotinib)

+

emapalumab

1 interaction

Monitor/Modify Tx

nilotinib + emapalumab

monitor potassium: combo may incr. risk of hypokalemia (additive effects)

• enalapril
Nilceya (nilotinib)

+

enalapril

1 interaction

Monitor/Modify Tx

nilotinib + enalapril

monitor potassium: combo may incr. risk of hyperkalemia (additive effects)

• enalaprilat
Nilceya (nilotinib)

+

enalaprilat

1 interaction

Monitor/Modify Tx

nilotinib + enalaprilat

monitor potassium: combo may incr. risk of hyperkalemia (additive effects)

• enoxaparin
Nilceya (nilotinib)

+

enoxaparin

1 interaction

Monitor/Modify Tx

nilotinib + enoxaparin

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

• epinephrine
Nilceya (nilotinib)

+

epinephrine

1 interaction

Monitor/Modify Tx

nilotinib + epinephrine

monitor potassium, ECG: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

• eplerenone
Nilceya (nilotinib)

+

eplerenone

1 interaction

Monitor/Modify Tx

nilotinib + eplerenone

ALL INDICATIONS: monitor potassium, renal fxn; POST-MI HFrEF: adjust max eplerenone dose to 25 mg/day; HTN: start eplerenone 25 mg qd, adjust max eplerenone dose to 50 mg/day: combo may incr. eplerenone levels, risk of hyperkalemia, other adverse effects (hepatic metabolism inhibited, additive effects)

• epoprostenol
Nilceya (nilotinib)

+

epoprostenol

1 interaction

Monitor/Modify Tx

nilotinib + epoprostenol

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

• eptifibatide
Nilceya (nilotinib)

+

eptifibatide

1 interaction

Monitor/Modify Tx

nilotinib + eptifibatide

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

• erlotinib
Nilceya (nilotinib)

+

erlotinib

1 interaction

Monitor/Modify Tx

nilotinib + erlotinib

monitor bleeding s/sx: combo may incr. erlotinib levels, risk of GI ulceration, perforation, bleeding (including life-threatening), other adverse effects (hepatic metabolism inhibited, additive effects)

• eslicarbazepine acetate
Nilceya (nilotinib)

+

eslicarbazepine acetate

1 interaction

Monitor/Modify Tx

nilotinib + eslicarbazepine acetate

monitor sodium: combo may decr. nilotinib levels, efficacy; may incr. risk of hyponatremia (including life-threatening), seizures (hepatic metabolism induced; additive effects)

• estazolam
Nilceya (nilotinib)

+

estazolam

1 interaction

Monitor/Modify Tx

nilotinib + estazolam

monitor respiratory rate; consider decr. estazolam dose: combo may incr. estazolam levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• estradiol (contraceptive)
Nilceya (nilotinib)

+

estradiol (contraceptive)

1 interaction

Monitor/Modify Tx

nilotinib + estradiol (contraceptive)

monitor thrombosis s/sx: combo may incr. estradiol levels, risk of thromboembolism, other adverse effects (hepatic metabolism inhibited)

• etelcalcetide
Nilceya (nilotinib)

+

etelcalcetide

1 interaction

Monitor/Modify Tx

nilotinib + etelcalcetide

monitor bleeding s/sx, calcium, ECG: combo may incr. risk of severe hypocalcemia (including life-threatening), QT prolongation, cardiac arrhythmias, seizures, GI ulceration, perforation, bleeding, including life-threatening (additive effects)

• ethacrynic acid
Nilceya (nilotinib)

+

ethacrynic acid

1 interaction

Monitor/Modify Tx

nilotinib + ethacrynic acid

monitor potassium, calcium, sodium: combo may incr. risk of hypokalemia, hypocalcemia, hyponatremia (additive effects)

• ethanol (alcoholic beverage)
Nilceya (nilotinib)

+

ethanol (alcoholic beverage)

1 interaction

Monitor/Modify Tx

nilotinib + ethanol (alcoholic beverage)

monitor bleeding signs/symptoms: combo may incr. risk of GI ulceration, perforation, bleeding, including life-threatening (additive effects)

• ethinyl estradiol (contraceptive)
Nilceya (nilotinib)

+

ethinyl estradiol (contraceptive)

1 interaction

Monitor/Modify Tx

nilotinib + ethinyl estradiol (contraceptive)

monitor thrombosis s/sx, especially if oral ethinyl estradiol dose >35 mcg/day: combo may incr. ethinyl estradiol levels, risk of thromboembolism, other adverse effects (hepatic metabolism inhibited)

• etodolac
Nilceya (nilotinib)

+

etodolac

1 interaction

Monitor/Modify Tx

nilotinib + etodolac

monitor potassium, bleeding s/sx: combo may incr. risk of hyperkalemia, GI ulceration, perforation, bleeding, including life-threatening (additive effects)

• etuvetidigene autotemcel
Nilceya (nilotinib)

+

etuvetidigene autotemcel

1 interaction

Monitor/Modify Tx

nilotinib + etuvetidigene autotemcel

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• evening primrose oil
Nilceya (nilotinib)

+

evening primrose oil

1 interaction

Monitor/Modify Tx

nilotinib + evening primrose oil

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

• everolimus
Nilceya (nilotinib)

+

everolimus

1 interaction

Monitor/Modify Tx

nilotinib + everolimus

BREAST CA, PNET, RENAL CELL CA, or RENAL ANGIOMYOLIPOMA w/ TSC: if also combined w/ P-gp inhibitor, decr. everolimus to 2.5 mg/day, may incr. to 5 mg/day if tolerated, monitor CBC; otherwise, monitor CBC; TSC-ASSOC. SEGA or TSC-ASSOC. PARTIAL-ONSET SEIZURES: if also combined w/ P-gp inhibitor, monitor everolimus levels, CBC and decr. everolimus 50%; give every other day if already on lowest available dose; otherwise, monitor everolimus levels, CBC; TRANSPLANT: monitor everolimus levels, CBC: combo may incr. everolimus levels, risk of myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

• exagamglogene autotemcel
Nilceya (nilotinib)

+

exagamglogene autotemcel

1 interaction

Monitor/Modify Tx

nilotinib + exagamglogene autotemcel

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• famotidine
Nilceya (nilotinib)

+

famotidine

1 interaction

Monitor/Modify Tx

nilotinib + famotidine

give nilotinib 2h before or 10h after famotidine: combo may decr. nilotinib levels, efficacy (absorption decreased at higher gastric pH)

• febuxostat
Nilceya (nilotinib)

+

febuxostat

1 interaction

Monitor/Modify Tx

nilotinib + febuxostat

monitor uric acid levels: combo may decr. febuxostat efficacy (antagonistic effects)

• fedratinib
Nilceya (nilotinib)

+

fedratinib

1 interaction

Monitor/Modify Tx

nilotinib + fedratinib

if fedratinib also combined w/ CYP2C19 inhibitor, monitor CBC, LFTs, ECG; otherwise, monitor ECG: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, myelosuppression, hepatotoxicity, other adverse effects (hepatic metabolism inhibited)

• felodipine
Nilceya (nilotinib)

+

felodipine

1 interaction

Monitor/Modify Tx

nilotinib + felodipine

monitor BP, HR: combo may incr. felodipine levels, risk of hypotension, reflex tachycardia, other adverse effects (hepatic metabolism inhibited)

• fenoprofen
Nilceya (nilotinib)

+

fenoprofen

1 interaction

Monitor/Modify Tx

nilotinib + fenoprofen

monitor potassium, bleeding s/sx: combo may incr. risk of hyperkalemia, GI ulceration, perforation, bleeding, including life-threatening (additive effects)

• fenugreek
Nilceya (nilotinib)

+

fenugreek

1 interaction

Monitor/Modify Tx

nilotinib + fenugreek

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

• filgrastim (G-CSF)
Nilceya (nilotinib)

+

filgrastim (G-CSF)

1 interaction

Monitor/Modify Tx

nilotinib + filgrastim (G-CSF)

admin. filgrastim at least 24h before or after myelosuppressive chemo: combo may decr. filgrastim efficacy (antagonistic effects)

• finerenone
Nilceya (nilotinib)

+

finerenone

1 interaction

Monitor/Modify Tx

nilotinib + finerenone

monitor potassium: combo may incr. finerenone levels, risk of hyperkalemia, other adverse effects (hepatic metabolism inhibited, additive effects)

• flucytosine
Nilceya (nilotinib)

+

flucytosine

1 interaction

Monitor/Modify Tx

nilotinib + flucytosine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• fludrocortisone
Nilceya (nilotinib)

+

fludrocortisone

1 interaction

Monitor/Modify Tx

nilotinib + fludrocortisone

monitor potassium, bleeding s/sx: combo may incr. risk of hypokalemia, GI ulceration, perforation, bleeding, including life-threatening (additive effects)

• fluphenazine
Nilceya (nilotinib)

+

fluphenazine

1 interaction

Monitor/Modify Tx

nilotinib + fluphenazine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• flurbiprofen
Nilceya (nilotinib)

+

flurbiprofen

1 interaction

Monitor/Modify Tx

nilotinib + flurbiprofen

monitor potassium, bleeding s/sx: combo may incr. risk of hyperkalemia, GI ulceration, perforation, bleeding, including life-threatening (additive effects)

• flurbiprofen ophthalmic
Nilceya (nilotinib)

+

flurbiprofen ophthalmic

1 interaction

Monitor/Modify Tx

nilotinib + flurbiprofen ophthalmic

monitor bleeding s/sx: combo may incr. risk of postop ocular bleeding (additive effects)

• fluvoxamine
Nilceya (nilotinib)

+

fluvoxamine

1 interaction

Monitor/Modify Tx

nilotinib + fluvoxamine

monitor sodium, bleeding s/sx: combo may incr. risk of hyponatremia, GI or other bleeding, including life-threatening (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake)

• fondaparinux
Nilceya (nilotinib)

+

fondaparinux

1 interaction

Monitor/Modify Tx

nilotinib + fondaparinux

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

• formoterol inhaled
Nilceya (nilotinib)

+

formoterol inhaled

1 interaction

Monitor/Modify Tx

nilotinib + formoterol inhaled

monitor ECG, electrolytes: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

• fosamprenavir
Nilceya (nilotinib)

+

fosamprenavir

1 interaction

Monitor/Modify Tx

nilotinib + fosamprenavir

monitor ECG, CBC: combo may incr. or decr. nilotinib levels, incr. risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects or decr. efficacy (hepatic metabolism altered)

• fosinopril
Nilceya (nilotinib)

+

fosinopril

1 interaction

Monitor/Modify Tx

nilotinib + fosinopril

monitor potassium: combo may incr. risk of hyperkalemia (additive effects)

• fostamatinib
Nilceya (nilotinib)

+

fostamatinib

1 interaction

Monitor/Modify Tx

nilotinib + fostamatinib

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• fostemsavir
Nilceya (nilotinib)

+

fostemsavir

1 interaction

Monitor/Modify Tx

nilotinib + fostemsavir

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• fruquintinib
Nilceya (nilotinib)

+

fruquintinib

1 interaction

Monitor/Modify Tx

nilotinib + fruquintinib

monitor bleeding s/sx: combo may incr. risk of GI ulceration, perforation, bleeding, including life-threatening (additive effects)

• furosemide
Nilceya (nilotinib)

+

furosemide

1 interaction

Monitor/Modify Tx

nilotinib + furosemide

monitor potassium, calcium, sodium: combo may incr. risk of hypokalemia, hypocalcemia, tetany, hyponatremia (additive effects)

• futibatinib
Nilceya (nilotinib)

+

futibatinib

1 interaction

Monitor/Modify Tx

nilotinib + futibatinib

monitor phosphate: combo may incr. futibatinib levels, risk of hyperphosphatemia, other adverse effects (hepatic metabolism inhibited)

• galantamine
Nilceya (nilotinib)

+

galantamine

1 interaction

Monitor/Modify Tx

nilotinib + galantamine

monitor bleeding s/sx: combo may incr. risk of GI ulceration, perforation, bleeding, including life-threatening (additive effects)

• garlic
Nilceya (nilotinib)

+

garlic

1 interaction

Monitor/Modify Tx

nilotinib + garlic

monitor bleeding s/sx, especially w/ supplemental garlic; dietary intake OK: combo may decr. nilotinib levels, efficacy; may incr. risk of GI or other bleeding, including life-threatening (hepatic metabolism induced; additive effects)

• gefitinib
Nilceya (nilotinib)

+

gefitinib

1 interaction

Monitor/Modify Tx

nilotinib + gefitinib

monitor bleeding s/sx: combo may incr. risk of GI ulceration, perforation, bleeding, including life-threatening (additive effects)

• gentamicin
Nilceya (nilotinib)

+

gentamicin

1 interaction

Monitor/Modify Tx

nilotinib + gentamicin

monitor calcium: combo may incr. risk of hypocalcemia, tetany (additive effects)

• gepirone
Nilceya (nilotinib)

+

gepirone

1 interaction

Monitor/Modify Tx

nilotinib + gepirone

monitor ECG, electrolytes; decr. gepirone dose 50%: combo may incr. gepirone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• ginkgo
Nilceya (nilotinib)

+

ginkgo

1 interaction

Monitor/Modify Tx

nilotinib + ginkgo

monitor bleeding s/sx: combo may decr. nilotinib levels, efficacy; may incr. risk of GI or other bleeding, including life-threatening (hepatic metabolism induced; additive effects)

• granisetron
Nilceya (nilotinib)

+

granisetron

1 interaction

Monitor/Modify Tx

nilotinib + granisetron

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• guanfacine
Nilceya (nilotinib)

+

guanfacine

1 interaction

Monitor/Modify Tx

nilotinib + guanfacine

decr. guanfacine ER dose 50%, consider decr. dose for immed.-release form: combo may incr. guanfacine levels, risk of adverse effects (hepatic metabolism inhibited)

• Haemophilus b vaccine
Nilceya (nilotinib)

+

Haemophilus b vaccine

1 interaction

Monitor/Modify Tx

nilotinib + Haemophilus b vaccine

if possible, vaccinate at least 2wk before starting nilotinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• heparin
Nilceya (nilotinib)

+

heparin

1 interaction

Monitor/Modify Tx

nilotinib + heparin

monitor bleeding s/sx, potassium: combo may incr. risk of GI or other bleeding (including life-threatening), hyperkalemia (additive effects)

• hepatitis A vaccine
Nilceya (nilotinib)

+

hepatitis A vaccine

1 interaction

Monitor/Modify Tx

nilotinib + hepatitis A vaccine

if possible, vaccinate at least 2wk before starting nilotinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• hepatitis B vaccine
Nilceya (nilotinib)

+

hepatitis B vaccine

1 interaction

Monitor/Modify Tx

nilotinib + hepatitis B vaccine

if possible, vaccinate at least 2wk before starting nilotinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• human papillomavirus vaccine
Nilceya (nilotinib)

+

human papillomavirus vaccine

1 interaction

Monitor/Modify Tx

nilotinib + human papillomavirus vaccine

if possible, vaccinate at least 2wk before starting nilotinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• hydrochlorothiazide
Nilceya (nilotinib)

+

hydrochlorothiazide

1 interaction

Monitor/Modify Tx

nilotinib + hydrochlorothiazide

monitor potassium, sodium: combo may incr. risk of hypokalemia, hyponatremia (additive effects; antagonistic effects)

• hydrocortisone
Nilceya (nilotinib)

+

hydrocortisone

1 interaction

Monitor/Modify Tx

nilotinib + hydrocortisone

monitor potassium, bleeding s/sx; consider decr. hydrocortisone dose: combo may incr. hydrocortisone levels, risk of hypokalemia, GI ulceration, perforation, bleeding (including life-threatening), systemic corticosteroid effects, including Cushing syndrome and adrenal suppression, other adverse effects (hepatic metabolism inhibited, additive effects)

• hydroxyurea
Nilceya (nilotinib)

+

hydroxyurea

1 interaction

Monitor/Modify Tx

nilotinib + hydroxyurea

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• ibandronate
Nilceya (nilotinib)

+

ibandronate

1 interaction

Monitor/Modify Tx

nilotinib + ibandronate

monitor calcium, bleeding s/sx if oral ibandronate use: combo may incr. risk of hypocalcemia, upper GI ulceration, perforation, bleeding, including life-threatening (additive effects)

• ibrutinib
Nilceya (nilotinib)

+

ibrutinib

1 interaction

Monitor/Modify Tx

nilotinib + ibrutinib

monitor bleeding s/sx; B-CELL MALIGNANCIES: decr. ibrutinib dose to 280 mg qd; CHRONIC GVHD: consider decr. ibrutinib dose: combo may incr. ibrutinib levels, risk of serious infection, myelosuppression, GI or other bleeding (including life-threatening), other adverse effects (hepatic metabolism inhibited, additive effects)

• ibuprofen
Nilceya (nilotinib)

+

ibuprofen

1 interaction

Monitor/Modify Tx

nilotinib + ibuprofen

monitor potassium, bleeding s/sx: combo may incr. risk of hyperkalemia, GI ulceration, perforation, bleeding, including life-threatening (additive effects)

• ibuprofen lysine
Nilceya (nilotinib)

+

ibuprofen lysine

1 interaction

Monitor/Modify Tx

nilotinib + ibuprofen lysine

monitor bleeding s/sx: combo may incr. risk of GI ulceration, perforation, bleeding, including life-threatening (additive effects)

• icosapent ethyl
Nilceya (nilotinib)

+

icosapent ethyl

1 interaction

Monitor/Modify Tx

nilotinib + icosapent ethyl

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

• ifosfamide
Nilceya (nilotinib)

+

ifosfamide

1 interaction

Monitor/Modify Tx

nilotinib + ifosfamide

monitor sodium: combo may decr. ifosfamide active metabolite levels, efficacy; may incr. risk of hyponatremia (hepatic metabolism altered, incr. or decr. active metabolite formation; additive effects)

• imatinib
Nilceya (nilotinib)

+

imatinib

1 interaction

Monitor/Modify Tx

nilotinib + imatinib

monitor ECG, CBC, bleeding s/sx: combo may incr. nilotinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, GI ulceration, perforation, bleeding (including life-threatening), other adverse effects (hepatic metabolism inhibited, additive effects)

• indapamide
Nilceya (nilotinib)

+

indapamide

1 interaction

Monitor/Modify Tx

nilotinib + indapamide

monitor potassium, sodium: combo may incr. risk of hypokalemia, severe hyponatremia (additive effects)

• indomethacin
Nilceya (nilotinib)

+

indomethacin

1 interaction

Monitor/Modify Tx

nilotinib + indomethacin

monitor potassium, bleeding s/sx: combo may incr. risk of hyperkalemia, GI ulceration, perforation, bleeding, including life-threatening (additive effects)

• influenza H5N1 vaccine
Nilceya (nilotinib)

+

influenza H5N1 vaccine

1 interaction

Monitor/Modify Tx

nilotinib + influenza H5N1 vaccine

if possible, vaccinate at least 2wk before starting nilotinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• influenza vaccine
Nilceya (nilotinib)

+

influenza vaccine

1 interaction

Monitor/Modify Tx

nilotinib + influenza vaccine

if possible, vaccinate at least 2wk before starting nilotinib tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• insulin
Nilceya (nilotinib)

+

insulin

1 interaction

Monitor/Modify Tx

nilotinib + insulin

monitor potassium: combo may incr. risk of hypokalemia (additive effects)

• interferon beta 1a
Nilceya (nilotinib)

+

interferon beta 1a

1 interaction

Monitor/Modify Tx

nilotinib + interferon beta 1a

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• interferon beta 1b
Nilceya (nilotinib)

+

interferon beta 1b

1 interaction

Monitor/Modify Tx

nilotinib + interferon beta 1b

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• interferon gamma 1b
Nilceya (nilotinib)

+

interferon gamma 1b

1 interaction

Monitor/Modify Tx

nilotinib + interferon gamma 1b

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• irbesartan
Nilceya (nilotinib)

+

irbesartan

1 interaction

Monitor/Modify Tx

nilotinib + irbesartan

monitor potassium: combo may incr. risk of hyperkalemia (additive effects)

• irinotecan
Nilceya (nilotinib)

+

irinotecan

1 interaction

Monitor/Modify Tx

nilotinib + irinotecan

monitor CBC: combo may incr. irinotecan and active metabolite levels, risk of serious infection, myelosuppression, other toxicities (hepatic metabolism inhibited)

• isavuconazonium
Nilceya (nilotinib)

+

isavuconazonium

1 interaction

Monitor/Modify Tx

nilotinib + isavuconazonium

monitor ECG, CBC: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited)

• isoproterenol
Nilceya (nilotinib)

+

isoproterenol

1 interaction

Monitor/Modify Tx

nilotinib + isoproterenol

monitor potassium: combo may incr. risk of hypokalemia (additive effects)

• Japanese encephalitis vaccine
Nilceya (nilotinib)

+

Japanese encephalitis vaccine

1 interaction

Monitor/Modify Tx

nilotinib + Japanese encephalitis vaccine

if possible, vaccinate at least 2wk before starting nilotinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ketoprofen
Nilceya (nilotinib)

+

ketoprofen

1 interaction

Monitor/Modify Tx

nilotinib + ketoprofen

monitor potassium, bleeding s/sx: combo may incr. risk of hyperkalemia, GI ulceration, perforation, bleeding, including life-threatening (additive effects)

• ketorolac
Nilceya (nilotinib)

+

ketorolac

1 interaction

Monitor/Modify Tx

nilotinib + ketorolac

monitor bleeding s/sx, potassium: combo may incr. risk of GI ulceration, perforation, bleeding (including life-threatening), hyperkalemia (additive effects)

• ketorolac ophthalmic
Nilceya (nilotinib)

+

ketorolac ophthalmic

1 interaction

Monitor/Modify Tx

nilotinib + ketorolac ophthalmic

monitor bleeding s/sx: combo may incr. risk of postop ocular bleeding (additive effects)

• landiolol
Nilceya (nilotinib)

+

landiolol

1 interaction

Monitor/Modify Tx

nilotinib + landiolol

monitor potassium, especially if renal impairment: combo may incr. risk of hyperkalemia (additive effects)

• lanthanum
Nilceya (nilotinib)

+

lanthanum

1 interaction

Monitor/Modify Tx

nilotinib + lanthanum

monitor bleeding s/sx: combo may incr. risk of GI ulceration, perforation, bleeding, including life-threatening (additive effects)

• lapatinib
Nilceya (nilotinib)

+

lapatinib

1 interaction

Monitor/Modify Tx

nilotinib + lapatinib

monitor ECG, electrolytes; consider decr. lapatinib dose: combo may incr. lapatinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• leflunomide
Nilceya (nilotinib)

+

leflunomide

1 interaction

Monitor/Modify Tx

nilotinib + leflunomide

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• lenacapavir
Nilceya (nilotinib)

+

lenacapavir

1 interaction

Monitor/Modify Tx

nilotinib + lenacapavir

monitor ECG, CBC during and x9mo after lenacapavir tx: combo may incr. nilotinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited)

• lenalidomide
Nilceya (nilotinib)

+

lenalidomide

1 interaction

Monitor/Modify Tx

nilotinib + lenalidomide

monitor potassium, calcium: combo may incr. risk of hypokalemia, hypocalcemia (additive effects)

• lenvatinib
Nilceya (nilotinib)

+

lenvatinib

1 interaction

Monitor/Modify Tx

nilotinib + lenvatinib

monitor ECG, electrolytes, bleeding s/sx: combo may incr. risk of QT prolongation, cardiac arrhythmias, hypocalcemia, GI ulceration, perforation, bleeding, including life-threatening (additive effects)

• letermovir
Nilceya (nilotinib)

+

letermovir

1 interaction

Monitor/Modify Tx

nilotinib + letermovir

monitor ECG, CBC: combo may incr. nilotinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited)

• levalbuterol inhaled
Nilceya (nilotinib)

+

levalbuterol inhaled

1 interaction

Monitor/Modify Tx

nilotinib + levalbuterol inhaled

monitor ECG, electrolytes: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

• levomilnacipran
Nilceya (nilotinib)

+

levomilnacipran

1 interaction

Monitor/Modify Tx

nilotinib + levomilnacipran

monitor sodium, bleeding s/sx: combo may incr. risk of hyponatremia, GI or other bleeding, including life-threatening (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake)

• licorice
Nilceya (nilotinib)

+

licorice

1 interaction

Monitor/Modify Tx

nilotinib + licorice

monitor potassium w/ large amounts of licorice: combo may incr. risk of hypokalemia (additive effects)

• lidocaine
Nilceya (nilotinib)

+

lidocaine

1 interaction

Monitor/Modify Tx

nilotinib + lidocaine

monitor lidocaine levels if lidocaine antiarrhythmic use; otherwise, monitor BP, HR: combo may incr. lidocaine levels, risk of hypotension, bradycardia, other adverse effects; risk may be higher with continuous infusion or higher doses for local anesthesia (hepatic metabolism inhibited)

• lifileucel
Nilceya (nilotinib)

+

lifileucel

1 interaction

Monitor/Modify Tx

nilotinib + lifileucel

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

• linezolid
Nilceya (nilotinib)

+

linezolid

1 interaction

Monitor/Modify Tx

nilotinib + linezolid

monitor sodium, CBC: combo may incr. risk of hyponatremia, myelosuppression (additive effects)

• losartan
Nilceya (nilotinib)

+

losartan

1 interaction

Monitor/Modify Tx

nilotinib + losartan

monitor potassium: combo may incr. risk of hyperkalemia (additive effects)

• lovotibeglogene autotemcel
Nilceya (nilotinib)

+

lovotibeglogene autotemcel

1 interaction

Monitor/Modify Tx

nilotinib + lovotibeglogene autotemcel

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• lumateperone
Nilceya (nilotinib)

+

lumateperone

1 interaction

Monitor/Modify Tx

nilotinib + lumateperone

monitor ECG, electrolytes; decr. lumateperone dose to 21 mg qd: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• lurasidone
Nilceya (nilotinib)

+

lurasidone

1 interaction

Monitor/Modify Tx

nilotinib + lurasidone

monitor ECG, electrolytes; decr. lurasidone start dose to 20 mg or decr. usual lurasidone dose 50%, max 80 mg/day: combo may incr. lurasidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• lymphocyte immune globulin, anti-thymocyte globulin
Nilceya (nilotinib)

+

lymphocyte immune globulin, anti-thymocyte globulin

1 interaction

Monitor/Modify Tx

nilotinib + lymphocyte immune globulin, anti-thymocyte globulin

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• magnesium carbonate
Nilceya (nilotinib)

+

magnesium carbonate

1 interaction

Monitor/Modify Tx

nilotinib + magnesium carbonate

separate admin. by at least 2h: combo may decr. nilotinib levels, efficacy (absorption decreased at higher gastric pH)

• magnesium citrate
Nilceya (nilotinib)

+

magnesium citrate

1 interaction

Monitor/Modify Tx

nilotinib + magnesium citrate

monitor sodium, potassium, consider monitoring ECG if magnesium citrate bowel prep use: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias, hyponatremia, seizures (additive effects)

• magnesium hydroxide
Nilceya (nilotinib)

+

magnesium hydroxide

1 interaction

Monitor/Modify Tx

nilotinib + magnesium hydroxide

separate admin. by at least 2h: combo may decr. nilotinib levels, efficacy (absorption decreased at higher gastric pH)

• magnesium oxide
Nilceya (nilotinib)

+

magnesium oxide

1 interaction

Monitor/Modify Tx

nilotinib + magnesium oxide

separate admin. by at least 2h: combo may decr. nilotinib levels, efficacy (absorption decreased at higher gastric pH)

• magnesium salicylate
Nilceya (nilotinib)

+

magnesium salicylate

1 interaction

Monitor/Modify Tx

nilotinib + magnesium salicylate

monitor bleeding s/sx: combo may incr. risk of GI ulceration, perforation, bleeding, including life-threatening (additive effects)

• mannitol
Nilceya (nilotinib)

+

mannitol

1 interaction

Monitor/Modify Tx

nilotinib + mannitol

monitor sodium, potassium, ECG: combo may incr. risk of hyponatremia (including life-threatening), seizures, hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

• mavorixafor
Nilceya (nilotinib)

+

mavorixafor

1 interaction

Monitor/Modify Tx

nilotinib + mavorixafor

monitor ECG, electrolytes: combo may incr. mavorixafor levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• meclofenamate
Nilceya (nilotinib)

+

meclofenamate

1 interaction

Monitor/Modify Tx

nilotinib + meclofenamate

monitor potassium, bleeding s/sx: combo may incr. risk of hyperkalemia, GI ulceration, perforation, bleeding, including life-threatening (additive effects)

• mefenamic acid
Nilceya (nilotinib)

+

mefenamic acid

1 interaction

Monitor/Modify Tx

nilotinib + mefenamic acid

monitor potassium, bleeding s/sx: combo may incr. risk of hyperkalemia, GI ulceration, perforation, bleeding, including life-threatening (additive effects)

• mefloquine
Nilceya (nilotinib)

+

mefloquine

1 interaction

Monitor/Modify Tx

nilotinib + mefloquine

monitor ECG, electrolytes: combo may incr. mefloquine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• meloxicam
Nilceya (nilotinib)

+

meloxicam

1 interaction

Monitor/Modify Tx

nilotinib + meloxicam

monitor potassium, bleeding s/sx: combo may incr. risk of hyperkalemia, GI ulceration, perforation, bleeding, including life-threatening (additive effects)

• meningococcal vaccine
Nilceya (nilotinib)

+

meningococcal vaccine

1 interaction

Monitor/Modify Tx

nilotinib + meningococcal vaccine

if possible, vaccinate at least 2wk before starting nilotinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• mercaptopurine
Nilceya (nilotinib)

+

mercaptopurine

1 interaction

Monitor/Modify Tx

nilotinib + mercaptopurine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• mesalamine
Nilceya (nilotinib)

+

mesalamine

1 interaction

Monitor/Modify Tx

nilotinib + mesalamine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• mesalamine rectal
Nilceya (nilotinib)

+

mesalamine rectal

1 interaction

Monitor/Modify Tx

nilotinib + mesalamine rectal

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• methazolamide
Nilceya (nilotinib)

+

methazolamide

1 interaction

Monitor/Modify Tx

nilotinib + methazolamide

monitor potassium, sodium: combo may incr. risk of hypokalemia, hyponatremia (additive effects)

• methotrexate
Nilceya (nilotinib)

+

methotrexate

1 interaction

Monitor/Modify Tx

nilotinib + methotrexate

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, GI ulceration, perforation, bleeding, including life-threatening (additive effects)

• methyl salicylate topical
Nilceya (nilotinib)

+

methyl salicylate topical

1 interaction

Monitor/Modify Tx

nilotinib + methyl salicylate topical

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects, systemic salicylate absorption may occur from topical use)

• methylprednisolone
Nilceya (nilotinib)

+

methylprednisolone

1 interaction

Monitor/Modify Tx

nilotinib + methylprednisolone

monitor potassium, bleeding s/sx: combo may incr. methylprednisolone levels, risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, hypokalemia, GI ulceration, perforation, bleeding, including life-threatening (hepatic metabolism inhibited, additive effects)

• metolazone
Nilceya (nilotinib)

+

metolazone

1 interaction

Monitor/Modify Tx

nilotinib + metolazone

monitor potassium, sodium: combo may incr. risk of hypokalemia, hyponatremia, including life-threatening (additive effects)

• metronidazole
Nilceya (nilotinib)

+

metronidazole

1 interaction

Monitor/Modify Tx

nilotinib + metronidazole

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• midostaurin
Nilceya (nilotinib)

+

midostaurin

1 interaction

Monitor/Modify Tx

nilotinib + midostaurin

monitor ECG, electrolytes, CBC: combo may incr. midostaurin levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

• milnacipran
Nilceya (nilotinib)

+

milnacipran

1 interaction

Monitor/Modify Tx

nilotinib + milnacipran

monitor sodium, bleeding s/sx: combo may incr. risk of hyponatremia, GI or other bleeding, including life-threatening (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake)

• mirtazapine
Nilceya (nilotinib)

+

mirtazapine

1 interaction

Monitor/Modify Tx

nilotinib + mirtazapine

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias, hyponatremia (additive effects)

• moexipril
Nilceya (nilotinib)

+

moexipril

1 interaction

Monitor/Modify Tx

nilotinib + moexipril

monitor potassium: combo may incr. risk of hyperkalemia (additive effects)

• monomethyl fumarate
Nilceya (nilotinib)

+

monomethyl fumarate

1 interaction

Monitor/Modify Tx

nilotinib + monomethyl fumarate

monitor bleeding s/sx: combo may incr. risk of GI ulceration, perforation, bleeding, including life-threatening (additive effects)

• motixafortide
Nilceya (nilotinib)

+

motixafortide

1 interaction

Monitor/Modify Tx

nilotinib + motixafortide

monitor potassium: combo may incr. risk of hypokalemia (additive effects)

• mycophenolate mofetil
Nilceya (nilotinib)

+

mycophenolate mofetil

1 interaction

Monitor/Modify Tx

nilotinib + mycophenolate mofetil

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, GI ulceration, perforation, bleeding, including life-threatening (additive effects)

• mycophenolic acid
Nilceya (nilotinib)

+

mycophenolic acid

1 interaction

Monitor/Modify Tx

nilotinib + mycophenolic acid

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, GI ulceration, perforation, bleeding, including life-threatening (additive effects)

• nabumetone
Nilceya (nilotinib)

+

nabumetone

1 interaction

Monitor/Modify Tx

nilotinib + nabumetone

monitor potassium, bleeding s/sx: combo may incr. risk of hyperkalemia, GI ulceration, perforation, bleeding, including life-threatening (additive effects)

• naproxen
Nilceya (nilotinib)

+

naproxen

1 interaction

Monitor/Modify Tx

nilotinib + naproxen

monitor potassium, bleeding s/sx: combo may incr. risk of hyperkalemia, GI ulceration, perforation, bleeding, including life-threatening (additive effects)

• nattokinase
Nilceya (nilotinib)

+

nattokinase

1 interaction

Monitor/Modify Tx

nilotinib + nattokinase

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

• necitumumab
Nilceya (nilotinib)

+

necitumumab

1 interaction

Monitor/Modify Tx

nilotinib + necitumumab

monitor potassium, calcium: combo may incr. risk of hypokalemia, hypocalcemia (additive effects)

• nepafenac ophthalmic
Nilceya (nilotinib)

+

nepafenac ophthalmic

1 interaction

Monitor/Modify Tx

nilotinib + nepafenac ophthalmic

monitor bleeding s/sx: combo may incr. risk of postop ocular bleeding (additive effects)

• netupitant
Nilceya (nilotinib)

+

netupitant

1 interaction

Monitor/Modify Tx

nilotinib + netupitant

monitor ECG, CBC: combo may incr. nilotinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited)

• niacin (vitamin B3)
Nilceya (nilotinib)

+

niacin (vitamin B3)

1 interaction

Monitor/Modify Tx

nilotinib + niacin (vitamin B3)

monitor platelets, bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

• nifedipine
Nilceya (nilotinib)

+

nifedipine

1 interaction

Monitor/Modify Tx

nilotinib + nifedipine

monitor BP, consider lowest nifedipine start dose: combo may incr. nifedipine levels, risk of hypotension, other adverse effects (hepatic metabolism inhibited)

• nimodipine
Nilceya (nilotinib)

+

nimodipine

1 interaction

Monitor/Modify Tx

nilotinib + nimodipine

monitor BP: combo may incr. nimodipine levels, risk of hypotension, other adverse effects (hepatic metabolism inhibited)

• nintedanib
Nilceya (nilotinib)

+

nintedanib

1 interaction

Monitor/Modify Tx

nilotinib + nintedanib

monitor bleeding s/sx: combo may incr. risk of GI ulceration, perforation, bleeding, including life-threatening (additive effects)

• nizatidine
Nilceya (nilotinib)

+

nizatidine

1 interaction

Monitor/Modify Tx

nilotinib + nizatidine

give nilotinib 2h before or 10h after nizatidine: combo may decr. nilotinib levels, efficacy (absorption decreased at higher gastric pH)

• nortriptyline
Nilceya (nilotinib)

+

nortriptyline

1 interaction

Monitor/Modify Tx

nilotinib + nortriptyline

monitor nortriptyline levels: combo may incr. nortriptyline levels, risk of adverse effects (hepatic metabolism inhibited)

• nusinersen
Nilceya (nilotinib)

+

nusinersen

1 interaction

Monitor/Modify Tx

nilotinib + nusinersen

monitor platelets, bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

• obinutuzumab
Nilceya (nilotinib)

+

obinutuzumab

1 interaction

Monitor/Modify Tx

nilotinib + obinutuzumab

monitor platelets, bleeding s/sx; consider holding nilotinib, especially during first obinutuzumab cycle: combo may incr. risk of severe bleeding, including life-threatening (additive effects)

• ofloxacin
Nilceya (nilotinib)

+

ofloxacin

1 interaction

Monitor/Modify Tx

nilotinib + ofloxacin

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• olodaterol inhaled
Nilceya (nilotinib)

+

olodaterol inhaled

1 interaction

Monitor/Modify Tx

nilotinib + olodaterol inhaled

monitor ECG, electrolytes: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

• olsalazine
Nilceya (nilotinib)

+

olsalazine

1 interaction

Monitor/Modify Tx

nilotinib + olsalazine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• omega-3-acid
Nilceya (nilotinib)

+

omega-3-acid

1 interaction

Monitor/Modify Tx

nilotinib + omega-3-acid

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

• osilodrostat
Nilceya (nilotinib)

+

osilodrostat

1 interaction

Monitor/Modify Tx

nilotinib + osilodrostat

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias, hypokalemia (hepatic metabolism inhibited, additive effects)

• oxaprozin
Nilceya (nilotinib)

+

oxaprozin

1 interaction

Monitor/Modify Tx

nilotinib + oxaprozin

monitor potassium, bleeding s/sx: combo may incr. risk of hyperkalemia, GI ulceration, perforation, bleeding, including life-threatening (additive effects)

• oxcarbazepine
Nilceya (nilotinib)

+

oxcarbazepine

1 interaction

Monitor/Modify Tx

nilotinib + oxcarbazepine

monitor sodium: combo may decr. nilotinib levels, efficacy; may incr. risk of hyponatremia, seizures (hepatic metabolism induced; additive effects)

• oxytocin
Nilceya (nilotinib)

+

oxytocin

1 interaction

Monitor/Modify Tx

nilotinib + oxytocin

monitor sodium: combo may incr. risk of hyponatremia (additive effects)

• palbociclib
Nilceya (nilotinib)

+

palbociclib

1 interaction

Monitor/Modify Tx

nilotinib + palbociclib

monitor CBC: combo may incr. palbociclib levels, risk of myelosuppression, other adverse effects (hepatic metabolism inhibited)

• palopegteriparatide
Nilceya (nilotinib)

+

palopegteriparatide

1 interaction

Monitor/Modify Tx

nilotinib + palopegteriparatide

monitor calcium: combo may incr. risk of hypocalcemia (additive effects)

• pamidronate
Nilceya (nilotinib)

+

pamidronate

1 interaction

Monitor/Modify Tx

nilotinib + pamidronate

monitor potassium, calcium: combo may incr. risk of hypocalcemia, hypokalemia (additive effects)

• panitumumab
Nilceya (nilotinib)

+

panitumumab

1 interaction

Monitor/Modify Tx

nilotinib + panitumumab

monitor potassium, calcium: combo may incr. risk of hypokalemia, hypocalcemia (additive effects)

• paroxetine
Nilceya (nilotinib)

+

paroxetine

1 interaction

Monitor/Modify Tx

nilotinib + paroxetine

monitor sodium, bleeding s/sx: combo may incr. risk of hyponatremia, GI or other bleeding, including life-threatening (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake)

• pegaspargase
Nilceya (nilotinib)

+

pegaspargase

1 interaction

Monitor/Modify Tx

nilotinib + pegaspargase

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

• pegfilgrastim (G-CSF)
Nilceya (nilotinib)

+

pegfilgrastim (G-CSF)

1 interaction

Monitor/Modify Tx

nilotinib + pegfilgrastim (G-CSF)

admin. pegfilgrastim >24h after or >14 days before myelosuppressive chemo: combo may decr. pegfilgrastim efficacy (antagonistic effects)

• peginterferon alfa 2a
Nilceya (nilotinib)

+

peginterferon alfa 2a

1 interaction

Monitor/Modify Tx

nilotinib + peginterferon alfa 2a

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• peginterferon beta 1a
Nilceya (nilotinib)

+

peginterferon beta 1a

1 interaction

Monitor/Modify Tx

nilotinib + peginterferon beta 1a

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• pegloticase
Nilceya (nilotinib)

+

pegloticase

1 interaction

Monitor/Modify Tx

nilotinib + pegloticase

monitor uric acid levels: combo may decr. pegloticase efficacy (antagonistic effects)

• penicillin G
Nilceya (nilotinib)

+

penicillin G

1 interaction

Monitor/Modify Tx

nilotinib + penicillin G

monitor bleeding s/sx, especially w/ large penicillin G doses and/or concomitant renal impairment: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

• pentosan polysulfate sodium
Nilceya (nilotinib)

+

pentosan polysulfate sodium

1 interaction

Monitor/Modify Tx

nilotinib + pentosan polysulfate sodium

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

• pentoxifylline
Nilceya (nilotinib)

+

pentoxifylline

1 interaction

Monitor/Modify Tx

nilotinib + pentoxifylline

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

• piperacillin
Nilceya (nilotinib)

+

piperacillin

1 interaction

Monitor/Modify Tx

nilotinib + piperacillin

monitor bleeding s/sx, especially w/ prolonged piperacillin tx and/or concomitant renal impairment: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

• piroxicam
Nilceya (nilotinib)

+

piroxicam

1 interaction

Monitor/Modify Tx

nilotinib + piroxicam

monitor potassium, bleeding s/sx: combo may incr. risk of hyperkalemia, GI ulceration, perforation, bleeding, including life-threatening (additive effects)

• pirtobrutinib
Nilceya (nilotinib)

+

pirtobrutinib

1 interaction

Monitor/Modify Tx

nilotinib + pirtobrutinib

monitor CBC, bleeding s/sx: combo may incr. pirtobrutinib levels, risk of serious infection, myelosuppression, GI or other bleeding (including life-threatening), other adverse effects (hepatic metabolism inhibited, additive effects)

• plasminogen, human
Nilceya (nilotinib)

+

plasminogen, human

1 interaction

Monitor/Modify Tx

nilotinib + plasminogen, human

monitor bleeding s/sx, especially during and x4h after plasminogen infusion: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

• pneumococcal vaccine
Nilceya (nilotinib)

+

pneumococcal vaccine

1 interaction

Monitor/Modify Tx

nilotinib + pneumococcal vaccine

if possible, vaccinate at least 2wk before starting nilotinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• poliovirus vaccine
Nilceya (nilotinib)

+

poliovirus vaccine

1 interaction

Monitor/Modify Tx

nilotinib + poliovirus vaccine

if possible, vaccinate at least 2wk before starting nilotinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• polyethylene glycol
Nilceya (nilotinib)

+

polyethylene glycol

1 interaction

Monitor/Modify Tx

nilotinib + polyethylene glycol

monitor sodium, potassium, consider monitoring ECG if polyethylene glycol bowel prep use: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias, hyponatremia, seizures (additive effects)

• polyethylene glycol/electrolytes
Nilceya (nilotinib)

+

polyethylene glycol/ electrolytes

1 interaction

Monitor/Modify Tx

nilotinib + polyethylene glycol/ electrolytes

monitor sodium, potassium, consider monitoring ECG: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias, hyponatremia, seizures (additive effects)

• ponatinib
Nilceya (nilotinib)

+

ponatinib

1 interaction

Monitor/Modify Tx

nilotinib + ponatinib

monitor CBC, bleeding s/sx: combo may incr. ponatinib levels, risk of serious infection, myelosuppression, GI ulceration, perforation, bleeding, (including life-threatening), other adverse effects (hepatic metabolism inhibited, additive effects)

• porfimer
Nilceya (nilotinib)

+

porfimer

1 interaction

Monitor/Modify Tx

nilotinib + porfimer

monitor bleeding s/sx: combo may incr. risk of GI ulceration, perforation, bleeding, including life-threatening (additive effects)

• potassium acid phosphate
Nilceya (nilotinib)

+

potassium acid phosphate

1 interaction

Monitor/Modify Tx

nilotinib + potassium acid phosphate

monitor potassium: combo may incr. risk of hyperkalemia (additive effects)

• potassium bicarbonate
Nilceya (nilotinib)

+

potassium bicarbonate

1 interaction

Monitor/Modify Tx

nilotinib + potassium bicarbonate

monitor potassium, ECG: combo may incr. risk of severe hyperkalemia, cardiac arrest (additive effects)

• potassium citrate
Nilceya (nilotinib)

+

potassium citrate

1 interaction

Monitor/Modify Tx

nilotinib + potassium citrate

monitor potassium, ECG: combo may incr. risk of severe hyperkalemia, cardiac arrest (additive effects)

• potassium iodide
Nilceya (nilotinib)

+

potassium iodide

1 interaction

Monitor/Modify Tx

nilotinib + potassium iodide

monitor potassium, ECG: combo may incr. risk of severe hyperkalemia, cardiac arrest (additive effects)

• prasugrel
Nilceya (nilotinib)

+

prasugrel

1 interaction

Monitor/Modify Tx

nilotinib + prasugrel

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

• prednisolone
Nilceya (nilotinib)

+

prednisolone

1 interaction

Monitor/Modify Tx

nilotinib + prednisolone

monitor potassium, bleeding s/sx: combo may incr. risk of hypokalemia, GI ulceration, perforation, bleeding, including life-threatening (additive effects)

• prednisone
Nilceya (nilotinib)

+

prednisone

1 interaction

Monitor/Modify Tx

nilotinib + prednisone

monitor potassium, bleeding s/sx: combo may decr. nilotinib levels, efficacy; may incr. risk of hypokalemia, GI ulceration, perforation, bleeding, including life-threatening (hepatic metabolism induced; additive effects)

• probenecid
Nilceya (nilotinib)

+

probenecid

1 interaction

Monitor/Modify Tx

nilotinib + probenecid

monitor uric acid levels: combo may decr. probenecid efficacy (antagonistic effects)

• proguanil
Nilceya (nilotinib)

+

proguanil

1 interaction

Monitor/Modify Tx

nilotinib + proguanil

monitor CBC, especially if concomitant renal impairment: combo may incr. risk of myelosuppression (additive effects)

• promethazine
Nilceya (nilotinib)

+

promethazine

1 interaction

Monitor/Modify Tx

nilotinib + promethazine

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• pyridostigmine
Nilceya (nilotinib)

+

pyridostigmine

1 interaction

Monitor/Modify Tx

nilotinib + pyridostigmine

monitor bleeding s/sx: combo may incr. risk of GI ulceration, perforation, bleeding, including life-threatening (additive effects)

• pyrimethamine
Nilceya (nilotinib)

+

pyrimethamine

1 interaction

Monitor/Modify Tx

nilotinib + pyrimethamine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• quinapril
Nilceya (nilotinib)

+

quinapril

1 interaction

Monitor/Modify Tx

nilotinib + quinapril

monitor potassium: combo may incr. risk of hyperkalemia (additive effects)

• ramipril
Nilceya (nilotinib)

+

ramipril

1 interaction

Monitor/Modify Tx

nilotinib + ramipril

monitor potassium: combo may incr. risk of hyperkalemia (additive effects)

• ramucirumab
Nilceya (nilotinib)

+

ramucirumab

1 interaction

Monitor/Modify Tx

nilotinib + ramucirumab

monitor sodium, bleeding s/sx: combo may incr. risk of hyponatremia, GI ulceration, perforation, bleeding, including life-threatening (additive effects)

• ranibizumab
Nilceya (nilotinib)

+

ranibizumab

1 interaction

Monitor/Modify Tx

nilotinib + ranibizumab

monitor bleeding s/sx: combo may incr. risk of ocular hemorrhage (additive effects)

• ranolazine
Nilceya (nilotinib)

+

ranolazine

1 interaction

Monitor/Modify Tx

nilotinib + ranolazine

monitor ECG, electrolytes; adjust ranolazine max dose to 1000 mg/day: combo may incr. ranolazine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• rasburicase
Nilceya (nilotinib)

+

rasburicase

1 interaction

Monitor/Modify Tx

nilotinib + rasburicase

monitor uric acid levels: combo may decr. rasburicase efficacy (antagonistic effects)

• red yeast rice
Nilceya (nilotinib)

+

red yeast rice

1 interaction

Monitor/Modify Tx

nilotinib + red yeast rice

monitor CK, myopathy sx w/ large amounts of red yeast rice: combo may incr. lovastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic metabolism inhibited, red yeast rice contains varying amounts of lovastatin)

• regorafenib
Nilceya (nilotinib)

+

regorafenib

1 interaction

Monitor/Modify Tx

nilotinib + regorafenib

monitor bleeding s/sx: combo may incr. risk of GI ulceration, perforation, bleeding, including life-threatening (additive effects)

• relugolix
Nilceya (nilotinib)

+

relugolix

1 interaction

Monitor/Modify Tx

nilotinib + relugolix

if prostate cancer use, monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• repaglinide
Nilceya (nilotinib)

+

repaglinide

1 interaction

Monitor/Modify Tx

nilotinib + repaglinide

monitor glucose: combo may incr. repaglinide levels, risk of hypoglycemia, other adverse effects (hepatic metabolism inhibited)

• respiratory syncytial virus vaccine
Nilceya (nilotinib)

+

respiratory syncytial virus vaccine

1 interaction

Monitor/Modify Tx

nilotinib + respiratory syncytial virus vaccine

if possible, vaccinate at least 2wk before starting nilotinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• resveratrol
Nilceya (nilotinib)

+

resveratrol

1 interaction

Monitor/Modify Tx

nilotinib + resveratrol

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

• reteplase
Nilceya (nilotinib)

+

reteplase

1 interaction

Monitor/Modify Tx

nilotinib + reteplase

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

• revakinagene taroretcel
Nilceya (nilotinib)

+

revakinagene taroretcel

1 interaction

Monitor/Modify Tx

nilotinib + revakinagene taroretcel

monitor bleeding s/sx: combo may incr. risk of ocular hemorrhage (additive effects)

• ribavirin
Nilceya (nilotinib)

+

ribavirin

1 interaction

Monitor/Modify Tx

nilotinib + ribavirin

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• rimegepant
Nilceya (nilotinib)

+

rimegepant

1 interaction

Monitor/Modify Tx

nilotinib + rimegepant

separate rimegepant doses by at least 48h: combo may incr. rimegepant levels, risk of adverse effects (hepatic metabolism inhibited)

• riociguat
Nilceya (nilotinib)

+

riociguat

1 interaction

Monitor/Modify Tx

nilotinib + riociguat

monitor BP: combo may incr. riociguat levels, risk of severe hypotension, other adverse effects (hepatic metabolism inhibited)

• risedronate
Nilceya (nilotinib)

+

risedronate

1 interaction

Monitor/Modify Tx

nilotinib + risedronate

monitor calcium, bleeding s/sx: combo may incr. risk of hypocalcemia, upper GI ulceration, perforation, bleeding, including life-threatening (additive effects)

• rituximab
Nilceya (nilotinib)

+

rituximab

1 interaction

Monitor/Modify Tx

nilotinib + rituximab

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• rivastigmine
Nilceya (nilotinib)

+

rivastigmine

1 interaction

Monitor/Modify Tx

nilotinib + rivastigmine

monitor bleeding s/sx: combo may incr. risk of GI ulceration, perforation, bleeding, including life-threatening (additive effects)

• romosozumab
Nilceya (nilotinib)

+

romosozumab

1 interaction

Monitor/Modify Tx

nilotinib + romosozumab

monitor calcium, especially w/ concomitant renal impairment: combo may incr. risk of hypocalcemia (additive effects)

• ruxolitinib
Nilceya (nilotinib)

+

ruxolitinib

1 interaction

Monitor/Modify Tx

nilotinib + ruxolitinib

monitor CBC: combo may incr. ruxolitinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited)

• ruxolitinib topical
Nilceya (nilotinib)

+

ruxolitinib topical

1 interaction

Monitor/Modify Tx

nilotinib + ruxolitinib topical

monitor CBC: combo may incr. ruxolitinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

• sacituzumab govitecan
Nilceya (nilotinib)

+

sacituzumab govitecan

1 interaction

Monitor/Modify Tx

nilotinib + sacituzumab govitecan

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias, hypokalemia (additive effects)

• salmeterol inhaled
Nilceya (nilotinib)

+

salmeterol inhaled

1 interaction

Monitor/Modify Tx

nilotinib + salmeterol inhaled

monitor ECG, electrolytes: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

• salsalate
Nilceya (nilotinib)

+

salsalate

1 interaction

Monitor/Modify Tx

nilotinib + salsalate

monitor bleeding s/sx: combo may incr. risk of GI ulceration, perforation, bleeding, including life-threatening (additive effects)

• sargramostim (GM-CSF)
Nilceya (nilotinib)

+

sargramostim (GM-CSF)

1 interaction

Monitor/Modify Tx

nilotinib + sargramostim (GM-CSF)

admin. sargramostim >24h before or after myelosuppressive chemo: combo may decr. sargramostim efficacy (antagonistic effects)

• sarilumab
Nilceya (nilotinib)

+

sarilumab

1 interaction

Monitor/Modify Tx

nilotinib + sarilumab

monitor CBC: combo may decr. nilotinib levels, efficacy; may incr. risk of myelosuppression (hepatic metabolism altered; sarilumab may reverse inflammatory cytokine-induced downregulation of CYP450 enzymes resulting in relative induction of enzymes upon tx start and downregulation upon D/C; additive effects)

• satralizumab
Nilceya (nilotinib)

+

satralizumab

1 interaction

Monitor/Modify Tx

nilotinib + satralizumab

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• saw palmetto
Nilceya (nilotinib)

+

saw palmetto

1 interaction

Monitor/Modify Tx

nilotinib + saw palmetto

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

• saxagliptin
Nilceya (nilotinib)

+

saxagliptin

1 interaction

Monitor/Modify Tx

nilotinib + saxagliptin

monitor glucose: combo may incr. saxagliptin levels, risk of hypoglycemia, other adverse effects (hepatic metabolism inhibited)

• sebetralstat
Nilceya (nilotinib)

+

sebetralstat

1 interaction

Monitor/Modify Tx

nilotinib + sebetralstat

monitor ECG, electrolytes; decr. sebetralstat dose to 300 mg, may give second 300 mg dose at least 3h after first dose if needed: combo may incr. sebetralstat levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• selinexor
Nilceya (nilotinib)

+

selinexor

1 interaction

Monitor/Modify Tx

nilotinib + selinexor

monitor potassium, sodium: combo may incr. risk of hypokalemia, hyponatremia, including life-threatening (additive effects)

• sepiapterin
Nilceya (nilotinib)

+

sepiapterin

1 interaction

Monitor/Modify Tx

nilotinib + sepiapterin

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

• sildenafil
Nilceya (nilotinib)

+

sildenafil

1 interaction

Monitor/Modify Tx

nilotinib + sildenafil

monitor BP: combo may incr. sildenafil levels, risk of hypotension (including syncope), priapism, other adverse effects (hepatic metabolism inhibited)

• sirolimus
Nilceya (nilotinib)

+

sirolimus

1 interaction

Monitor/Modify Tx

nilotinib + sirolimus

monitor sirolimus levels, CBC: combo may incr. sirolimus levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

• sirolimus albumin-bound
Nilceya (nilotinib)

+

sirolimus albumin-bound

1 interaction

Monitor/Modify Tx

nilotinib + sirolimus albumin-bound

decr. sirolimus albumin-bound dose to 56 mg/m2; monitor CBC, potassium, bleeding s/sx: combo may incr. sirolimus albumin-bound levels, risk of serious infection, myelosuppression, GI or other bleeding (including life-threatening), hypokalemia, other adverse effects (hepatic metabolism inhibited, additive effects)

• smallpox/mpox vaccine, live
Nilceya (nilotinib)

+

smallpox/ mpox vaccine, live

1 interaction

Monitor/Modify Tx

nilotinib + smallpox/ mpox vaccine, live

consider vaccinating at least 4wk before or 3mo after nilotinib tx: combo may result in inadequate vaccine response (immunosuppressive effects)

• sodium benzoate
Nilceya (nilotinib)

+

sodium benzoate

1 interaction

Monitor/Modify Tx

nilotinib + sodium benzoate

monitor potassium, especially if hyperammonemia use: combo may incr. risk of hypokalemia (additive effects)

• sodium bicarbonate
Nilceya (nilotinib)

+

sodium bicarbonate

1 interaction

Monitor/Modify Tx

nilotinib + sodium bicarbonate

separate admin. w/ oral sodium bicarbonate by at least 2h: combo may decr. nilotinib levels, efficacy (absorption decreased at higher gastric pH)

• sodium citrate
Nilceya (nilotinib)

+

sodium citrate

1 interaction

Monitor/Modify Tx

nilotinib + sodium citrate

separate admin. by at least 2h: combo may decr. nilotinib levels, efficacy (absorption decreased at higher gastric pH)

• sodium phenylacetate
Nilceya (nilotinib)

+

sodium phenylacetate

1 interaction

Monitor/Modify Tx

nilotinib + sodium phenylacetate

monitor potassium: combo may incr. risk of hypokalemia (additive effects)

• sodium phenylbutyrate
Nilceya (nilotinib)

+

sodium phenylbutyrate

1 interaction

Monitor/Modify Tx

nilotinib + sodium phenylbutyrate

monitor potassium: combo may incr. risk of hypokalemia (additive effects)

• sodium polystyrene sulfonate
Nilceya (nilotinib)

+

sodium polystyrene sulfonate

1 interaction

Monitor/Modify Tx

nilotinib + sodium polystyrene sulfonate

monitor calcium, potassium, ECG: combo may incr. risk of hypocalcemia, hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

• sodium thiosulfate
Nilceya (nilotinib)

+

sodium thiosulfate

1 interaction

Monitor/Modify Tx

nilotinib + sodium thiosulfate

if ototoxicity risk reduction use, monitor potassium; otherwise, caution advised: combo may incr. risk of hypokalemia (additive effects)

• sodium zirconium cyclosilicate
Nilceya (nilotinib)

+

sodium zirconium cyclosilicate

1 interaction

Monitor/Modify Tx

nilotinib + sodium zirconium cyclosilicate

give nilotinib at least 2h before or 2h after sodium zirconium cyclosilicate: combo may decr. nilotinib levels, efficacy (absorption decreased at higher gastric pH)

• sotatercept
Nilceya (nilotinib)

+

sotatercept

1 interaction

Monitor/Modify Tx

nilotinib + sotatercept

monitor platelets, bleeding s/sx: combo may incr. risk of GI or other bleeding, including severe or life-threatening (additive effects)

• sparsentan
Nilceya (nilotinib)

+

sparsentan

1 interaction

Monitor/Modify Tx

nilotinib + sparsentan

monitor BP, potassium, renal fxn: combo may incr. sparsentan levels, risk of hypotension (including orthostasis, syncope), hyperkalemia, edema, nephrotoxicity, other adverse effects (hepatic metabolism inhibited, additive effects)

• spironolactone
Nilceya (nilotinib)

+

spironolactone

1 interaction

Monitor/Modify Tx

nilotinib + spironolactone

monitor potassium, sodium: combo may incr. risk of severe hyperkalemia, hyponatremia (additive effects)

• stiripentol
Nilceya (nilotinib)

+

stiripentol

1 interaction

Monitor/Modify Tx

nilotinib + stiripentol

monitor CBC: combo may decr. nilotinib levels, efficacy; may incr. risk of myelosuppression (hepatic metabolism possibly induced; additive effects)

• succimer
Nilceya (nilotinib)

+

succimer

1 interaction

Monitor/Modify Tx

nilotinib + succimer

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• succinylcholine
Nilceya (nilotinib)

+

succinylcholine

1 interaction

Monitor/Modify Tx

nilotinib + succinylcholine

monitor potassium: combo may incr. risk of hyperkalemia (additive effects)

• sulfasalazine
Nilceya (nilotinib)

+

sulfasalazine

1 interaction

Monitor/Modify Tx

nilotinib + sulfasalazine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• sulfate bowel prep
Nilceya (nilotinib)

+

sulfate bowel prep

1 interaction

Monitor/Modify Tx

nilotinib + sulfate bowel prep

monitor sodium, potassium, consider monitoring ECG: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias, hyponatremia, seizures (additive effects)

• sulindac
Nilceya (nilotinib)

+

sulindac

1 interaction

Monitor/Modify Tx

nilotinib + sulindac

monitor potassium, bleeding s/sx: combo may incr. risk of hyperkalemia, GI ulceration, perforation, bleeding, including life-threatening (additive effects)

• sunitinib
Nilceya (nilotinib)

+

sunitinib

1 interaction

Monitor/Modify Tx

nilotinib + sunitinib

monitor ECG, electrolytes, bleeding s/sx: combo may incr. sunitinib levels, risk of QT prolongation, cardiac arrhythmias, GI ulceration, perforation, bleeding (including life-threatening), other adverse effects (hepatic metabolism inhibited, additive effects)

• suvorexant
Nilceya (nilotinib)

+

suvorexant

1 interaction

Monitor/Modify Tx

nilotinib + suvorexant

decr. suvorexant dose to 5 mg, max 10 mg/day: combo may incr. suvorexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• suzetrigine
Nilceya (nilotinib)

+

suzetrigine

1 interaction

Monitor/Modify Tx

nilotinib + suzetrigine

start suzetrigine 100 mg x1 at least 1h before or 2h after food, after 12h give 50 mg q12h x3 doses, then after 12h give 50mg q24h: combo may incr. suzetrigine and active metabolite levels, risk of adverse effects; may decr. nilotinib levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• tadalafil
Nilceya (nilotinib)

+

tadalafil

1 interaction

Monitor/Modify Tx

nilotinib + tadalafil

monitor BP: combo may incr. tadalafil levels, risk of hypotension, priapism, other adverse effects (hepatic metabolism inhibited)

• tafasitamab
Nilceya (nilotinib)

+

tafasitamab

1 interaction

Monitor/Modify Tx

nilotinib + tafasitamab

monitor potassium: combo may incr. risk of hypokalemia (additive effects)

• tamsulosin
Nilceya (nilotinib)

+

tamsulosin

1 interaction

Monitor/Modify Tx

nilotinib + tamsulosin

monitor BP, especially w/ tamsulosin dose >0.4 mg: combo may incr. tamsulosin levels, risk of hypotension (including orthostasis, syncope), other adverse effects (hepatic metabolism inhibited)

• telmisartan
Nilceya (nilotinib)

+

telmisartan

1 interaction

Monitor/Modify Tx

nilotinib + telmisartan

monitor potassium: combo may incr. risk of hyperkalemia (additive effects)

• temsirolimus
Nilceya (nilotinib)

+

temsirolimus

1 interaction

Monitor/Modify Tx

nilotinib + temsirolimus

monitor CBC, bleeding s/sx; consider decr. temsirolimus dose: combo may incr. temsirolimus and active metabolite sirolimus levels, risk of serious infection, myelosuppression, GI or other bleeding (including life-threatening), other adverse effects (hepatic metabolism inhibited, additive effects)

• tenecteplase
Nilceya (nilotinib)

+

tenecteplase

1 interaction

Monitor/Modify Tx

nilotinib + tenecteplase

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

• teplizumab
Nilceya (nilotinib)

+

teplizumab

1 interaction

Monitor/Modify Tx

nilotinib + teplizumab

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• terbutaline
Nilceya (nilotinib)

+

terbutaline

1 interaction

Monitor/Modify Tx

nilotinib + terbutaline

monitor ECG, electrolytes: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

• teriflunomide
Nilceya (nilotinib)

+

teriflunomide

1 interaction

Monitor/Modify Tx

nilotinib + teriflunomide

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• tezacaftor/ivacaftor
Nilceya (nilotinib)

+

tezacaftor/ ivacaftor

1 interaction

Monitor/Modify Tx

nilotinib + tezacaftor/ ivacaftor

decr. dose by alternating tezacaftor/ivacaftor tab and ivacaftor tab at morning dose, no evening doses: combo may incr. tezacaftor/ivacaftor levels, risk of adverse effects (hepatic metabolism inhibited)

• thalidomide
Nilceya (nilotinib)

+

thalidomide

1 interaction

Monitor/Modify Tx

nilotinib + thalidomide

monitor CBC, calcium: combo may incr. risk of myelosuppression, hypocalcemia (additive effects)

• ticagrelor
Nilceya (nilotinib)

+

ticagrelor

1 interaction

Monitor/Modify Tx

nilotinib + ticagrelor

monitor bleeding s/sx: combo may incr. ticagrelor levels, risk of dyspnea, GI or other bleeding (including life-threatening), other adverse effects (hepatic metabolism inhibited, additive effects)

• tick-borne encephalitis vaccine
Nilceya (nilotinib)

+

tick-borne encephalitis vaccine

1 interaction

Monitor/Modify Tx

nilotinib + tick-borne encephalitis vaccine

if possible, vaccinate at least 2wk before starting nilotinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• tirofiban
Nilceya (nilotinib)

+

tirofiban

1 interaction

Monitor/Modify Tx

nilotinib + tirofiban

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

• tisotumab vedotin
Nilceya (nilotinib)

+

tisotumab vedotin

1 interaction

Monitor/Modify Tx

nilotinib + tisotumab vedotin

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

• tivozanib
Nilceya (nilotinib)

+

tivozanib

1 interaction

Monitor/Modify Tx

nilotinib + tivozanib

monitor bleeding s/sx: combo may incr. risk of GI ulceration, perforation, bleeding, including life-threatening (additive effects)

• tobramycin
Nilceya (nilotinib)

+

tobramycin

1 interaction

Monitor/Modify Tx

nilotinib + tobramycin

monitor calcium: combo may incr. risk of hypocalcemia (additive effects)

• tocilizumab
Nilceya (nilotinib)

+

tocilizumab

1 interaction

Monitor/Modify Tx

nilotinib + tocilizumab

monitor CBC, bleeding s/sx: combo may decr. nilotinib levels, efficacy; may incr. risk of myelosuppression, GI ulceration, perforation, bleeding, including life-threatening (hepatic metabolism altered; tocilizumab may reverse inflammatory cytokine-induced downregulation of CYP450 enzymes resulting in relative induction of enzymes; additive effects)

• tofacitinib
Nilceya (nilotinib)

+

tofacitinib

1 interaction

Monitor/Modify Tx

nilotinib + tofacitinib

ALL USES: monitor CBC; if also combined w/ strong CYP2C19 inhibitor, adjust tofacitinib as follows: ADULT RHEUMATOID or PSORIATIC ARTHRITIS or ANKYLOSING SPONDYLITIS: decr. to 5 mg qd; ADULT ULCERATIVE COLITIS: decr. induction to 5 mg bid using tabs or 11 mg qd using XR tab for up to 16 wks, followed by 5 mg qd maintenance using tabs; do not use XR tabs for maintenance doses; PEDIATRIC PSORIATIC ARTHRITIS, POLYARTICULAR COURSE JUVENILE IDIOPATHIC ARTHRITIS: decr. usual bid dose to qd: combo may incr. tofacitinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

• tolmetin
Nilceya (nilotinib)

+

tolmetin

1 interaction

Monitor/Modify Tx

nilotinib + tolmetin

monitor potassium, bleeding s/sx: combo may incr. risk of hyperkalemia, GI ulceration, perforation, bleeding, including life-threatening (additive effects)

• tolterodine
Nilceya (nilotinib)

+

tolterodine

1 interaction

Monitor/Modify Tx

nilotinib + tolterodine

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• topiramate
Nilceya (nilotinib)

+

topiramate

1 interaction

Monitor/Modify Tx

nilotinib + topiramate

monitor potassium: combo may decr. nilotinib levels, efficacy; may incr. risk of hypokalemia (hepatic metabolism induced; additive effects)

• torsemide
Nilceya (nilotinib)

+

torsemide

1 interaction

Monitor/Modify Tx

nilotinib + torsemide

monitor potassium, calcium, sodium: combo may incr. risk of hypokalemia, hypocalcemia, hyponatremia (additive effects)

• tovorafenib
Nilceya (nilotinib)

+

tovorafenib

1 interaction

Monitor/Modify Tx

nilotinib + tovorafenib

monitor bleeding s/sx: combo may decr. nilotinib levels, efficacy; incr. risk of GI or other bleeding, including life-threatening (hepatic metabolism induced; additive effects)

• trabectedin
Nilceya (nilotinib)

+

trabectedin

1 interaction

Monitor/Modify Tx

nilotinib + trabectedin

monitor CBC, cardiac function (including LVEF), LFTs: combo may incr. trabectedin levels, risk of myelosuppression, cardiotoxicity, hepatotoxicity, other adverse effects (hepatic metabolism inhibited)

• trametinib
Nilceya (nilotinib)

+

trametinib

1 interaction

Monitor/Modify Tx

nilotinib + trametinib

monitor bleeding s/sx: combo may incr. risk of GI ulceration, perforation, bleeding, including life-threatening (additive effects)

• trandolapril
Nilceya (nilotinib)

+

trandolapril

1 interaction

Monitor/Modify Tx

nilotinib + trandolapril

monitor potassium: combo may incr. risk of hyperkalemia (additive effects)

• treprostinil
Nilceya (nilotinib)

+

treprostinil

1 interaction

Monitor/Modify Tx

nilotinib + treprostinil

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

• triamcinolone
Nilceya (nilotinib)

+

triamcinolone

1 interaction

Monitor/Modify Tx

nilotinib + triamcinolone

monitor potassium, bleeding s/sx: combo may incr. risk of hypokalemia, GI ulceration, perforation, bleeding, including life-threatening (additive effects)

• triamterene
Nilceya (nilotinib)

+

triamterene

1 interaction

Monitor/Modify Tx

nilotinib + triamterene

monitor potassium, sodium: combo may incr. risk of severe hyperkalemia, hyponatremia (additive effects)

• triazolam
Nilceya (nilotinib)

+

triazolam

1 interaction

Monitor/Modify Tx

nilotinib + triazolam

monitor respiratory rate; consider decr. triazolam dose: combo may incr. triazolam levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• trimethoprim
Nilceya (nilotinib)

+

trimethoprim

1 interaction

Monitor/Modify Tx

nilotinib + trimethoprim

monitor CBC, potassium: combo may incr. risk of myelosuppression, hyperkalemia (additive effects)

• typhoid vaccine
Nilceya (nilotinib)

+

typhoid vaccine

1 interaction

Monitor/Modify Tx

nilotinib + typhoid vaccine

if possible, vaccinate at least 2wk before starting nilotinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ubrogepant
Nilceya (nilotinib)

+

ubrogepant

1 interaction

Monitor/Modify Tx

nilotinib + ubrogepant

limit ubrogepant dose to 50 mg, may give second 50 mg dose after 24h if needed: combo may incr. ubrogepant levels, risk of adverse effects (hepatic metabolism inhibited)

• upadacitinib
Nilceya (nilotinib)

+

upadacitinib

1 interaction

Monitor/Modify Tx

nilotinib + upadacitinib

monitor CBC, bleeding s/sx: combo may incr. upadacitinib levels, risk of serious infection, myelosuppression, GI ulceration, perforation, bleeding (including life-threatening), other adverse effects (hepatic metabolism inhibited, additive effects)

• vadadustat
Nilceya (nilotinib)

+

vadadustat

1 interaction

Monitor/Modify Tx

nilotinib + vadadustat

monitor bleeding s/sx: combo may incr. risk of GI ulceration, perforation, bleeding, including life-threatening (additive effects)

• valbenazine
Nilceya (nilotinib)

+

valbenazine

1 interaction

Monitor/Modify Tx

nilotinib + valbenazine

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• valproic acid
Nilceya (nilotinib)

+

valproic acid

1 interaction

Monitor/Modify Tx

nilotinib + valproic acid

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, GI or other bleeding, including life-threatening (additive effects)

• vamorolone
Nilceya (nilotinib)

+

vamorolone

1 interaction

Monitor/Modify Tx

nilotinib + vamorolone

monitor potassium, bleeding s/sx: combo may decr. nilotinib levels, efficacy; may incr. risk of hypokalemia, GI ulceration, perforation, bleeding, including life-threatening (hepatic metabolism possibly induced; additive effects)

• vancomycin
Nilceya (nilotinib)

+

vancomycin

1 interaction

Monitor/Modify Tx

nilotinib + vancomycin

VANCOMYCIN IV: monitor CBC, especially w/ long-term vancomycin; VANCOMYCIN PO use OK: combo may incr. risk of myelosuppression (additive effects)

• vanzacaftor/tezacaftor/deutivacaftor
Nilceya (nilotinib)

+

vanzacaftor/ tezacaftor/ deutivacaftor

1 interaction

Monitor/Modify Tx

nilotinib + vanzacaftor/ tezacaftor/ deutivacaftor

6-11 YO AND WT <40 KG: decr. vanzacaftor/tezacaftor/deutivacaftor dose to two tablets (4 mg/20 mg/50 mg each) qod; 6-11 YO AND WT 40 KG AND ABOVE: decr. vanzacaftor/tezacaftor/deutivacaftor dose to one tablet (10 mg/50 mg/125 mg) qod; 12 YO AND OLDER: decr. vanzacaftor/tezacaftor/deutivacaftor dose to one tablet (10 mg/50 mg/125 mg) qod: combo may incr. vanzacaftor/tezacaftor/deutivacaftor levels, risk of adverse effects (hepatic metabolism inhibited)

• vasopressin
Nilceya (nilotinib)

+

vasopressin

1 interaction

Monitor/Modify Tx

nilotinib + vasopressin

monitor sodium: combo may incr. risk of hyponatremia (additive effects)

• venlafaxine
Nilceya (nilotinib)

+

venlafaxine

1 interaction

Monitor/Modify Tx

nilotinib + venlafaxine

monitor ECG, electrolytes, bleeding s/sx: combo may incr. risk of QT prolongation, cardiac arrhythmias, hyponatremia, GI or other bleeding, including life-threatening (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake)

• verapamil
Nilceya (nilotinib)

+

verapamil

1 interaction

Monitor/Modify Tx

nilotinib + verapamil

monitor ECG, CBC: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, hypotension, bradycardia, AV block, myelosuppression, other adverse effects (hepatic metabolism inhibited)

• vilanterol inhaled
Nilceya (nilotinib)

+

vilanterol inhaled

1 interaction

Monitor/Modify Tx

nilotinib + vilanterol inhaled

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias, hypokalemia (additive effects)

• vilazodone
Nilceya (nilotinib)

+

vilazodone

1 interaction

Monitor/Modify Tx

nilotinib + vilazodone

monitor bleeding s/sx, sodium: combo may incr. vilazodone levels, risk of GI or other bleeding (including life-threatening), hyponatremia, other adverse effects (hepatic metabolism inhibited, additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake)

• vinblastine
Nilceya (nilotinib)

+

vinblastine

1 interaction

Monitor/Modify Tx

nilotinib + vinblastine

monitor CBC: combo may incr. vinblastine levels, risk of serious infection, myelosuppression, autonomic neuropathy, other adverse effects; may decr. nilotinib levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• vincristine
Nilceya (nilotinib)

+

vincristine

1 interaction

Monitor/Modify Tx

nilotinib + vincristine

monitor CBC: combo may incr. vincristine levels, risk of serious infection, myelosuppression, autonomic neuropathy, other adverse effects (hepatic metabolism inhibited)

• vinorelbine
Nilceya (nilotinib)

+

vinorelbine

1 interaction

Monitor/Modify Tx

nilotinib + vinorelbine

monitor CBC: combo may incr. vinorelbine levels, risk of serious infection, myelosuppression, autonomic neuropathy, other adverse effects (hepatic metabolism inhibited)

• vinpocetine
Nilceya (nilotinib)

+

vinpocetine

1 interaction

Monitor/Modify Tx

nilotinib + vinpocetine

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

• voclosporin
Nilceya (nilotinib)

+

voclosporin

1 interaction

Monitor/Modify Tx

nilotinib + voclosporin

monitor ECG, electrolytes, renal fxn; decr. voclosporin morning dose to 15.8 mg and evening dose to 7.9 mg: combo may incr. voclosporin levels, risk of QT prolongation, cardiac arrhythmias, severe hyperkalemia, serious infection, nephrotoxicity, other adverse effects (hepatic metabolism inhibited, additive effects)

• vorapaxar
Nilceya (nilotinib)

+

vorapaxar

1 interaction

Monitor/Modify Tx

nilotinib + vorapaxar

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

• vortioxetine
Nilceya (nilotinib)

+

vortioxetine

1 interaction

Monitor/Modify Tx

nilotinib + vortioxetine

monitor sodium, bleeding s/sx: combo may incr. risk of hyponatremia, GI or other bleeding, including life-threatening (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake)

• warfarin
Nilceya (nilotinib)

+

warfarin

1 interaction

Monitor/Modify Tx

nilotinib + warfarin

monitor INR, bleeding s/sx, especially during initiation/titration: combo may incr. warfarin levels, risk of GI or other bleeding (including life-threatening), other adverse effects (hepatic metabolism inhibited, synergistic effects)

• willow bark
Nilceya (nilotinib)

+

willow bark

1 interaction

Monitor/Modify Tx

nilotinib + willow bark

monitor bleeding s/sx: combo may incr. risk of GI ulceration, perforation, bleeding, including life-threatening (additive effects, willow bark may contain salicylates)

• zanubrutinib
Nilceya (nilotinib)

+

zanubrutinib

1 interaction

Monitor/Modify Tx

nilotinib + zanubrutinib

decr. zanubrutinib dose to 80 mg bid; monitor CBC, bleeding s/sx: combo may incr. zanubrutinib levels, risk of serious infection, myelosuppression, GI or other bleeding (including life-threatening), other adverse effects; may decr. nilotinib levels, efficacy (hepatic metabolism inhibited, additive effects; hepatic metabolism induced)

• zidovudine
Nilceya (nilotinib)

+

zidovudine

1 interaction

Monitor/Modify Tx

nilotinib + zidovudine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• ziv-aflibercept
Nilceya (nilotinib)

+

ziv-aflibercept

1 interaction

Monitor/Modify Tx

nilotinib + ziv-aflibercept

monitor bleeding s/sx: combo may incr. risk of GI ulceration, perforation, bleeding, including life-threatening (additive effects)

• zoledronic acid
Nilceya (nilotinib)

+

zoledronic acid

1 interaction

Monitor/Modify Tx

nilotinib + zoledronic acid

monitor calcium: combo may incr. risk of hypocalcemia (additive effects)

• zonisamide
Nilceya (nilotinib)

+

zonisamide

1 interaction

Monitor/Modify Tx

nilotinib + zonisamide

monitor potassium: combo may incr. risk of hypokalemia (additive effects)